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Preface 
Fascinating: this is the word that best expresses my PhD scholarship. 
Fascinating for the research activity, fascinating for the friendships arisen from 
scientific collaborations, fascinating for the chance to work with different people 
and in foreign countries, fascinating for the impact that all of this had and still has 
on me. Express feelings, satisfaction, hope and even the frustrations that the 
research activity involves is not simple, and transfer them to a thesis is certainly 
arduous; however, I hope to convey the mix of passion, dedication, perseverance 
and romance, which have accompanied me through this experience. 
During my PhD scholarship I worked mainly on computational chemistry, but also 
on wet chemistry, like organic synthesis and enzymatic inhibition assays. This has 
made me aware of the various aspects that characterize the different medicinal 
chemistry applications, and how these are linked together, allowing not only to 
immerse myself in the specific laboratory practice, but also to gain an overview of 
the manifold scientific research process.  
I couldn’t have asked for anything better. 
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Introduction 
The present doctoral thesis is the result of the work carried out during the three 
years of my PhD scholarship at the Rome Center for Molecular Design laboratory 
(RCMD, Department of Chemistry and Drug Technologies, Sapienza University of 
Rome), under the supervision of Prof. Rino Ragno. The research activity was 
focused mainly on the design, optimization and application of computational 
strategies to derive quantitative structure-activity relationships (QSAR, 3-D 
QSAR, and COMBINE) on different molecular classes of current interest, such as: 
opioid receptor antagonists (OPAs), Hepatitis C Virus NS5B-Polymerase 
Inhibitors (NS5B-NNIs), Hystone Deacetylase Inhibitors (HDACIs), Anti-
tubercular agents, vascular endothelial growth factor receptor-2 (VEGFR-2) 
inhibitors, HSP90 inhibitors, HIV-1 reverse transcriptase inhibitors (NNRTIs), 
Bovine Serum Amine Oxidase (BSAO) substrates, etc... Moreover two research 
periods abroad were performed: the first framed in a LLP Erasmus program 
collaboration, was conducted for six months at the Laboratoire d'Ingénierie et 
Moléculaire Pharmacologique Biochimie (LIMBP) of the Université de Lorraine 
Metz (France), directed by Prof. Gilbert Kirsch, and characterized by the 
application of organic synthesis to obtain new thienopyrimidinone derivatives as 
potential inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2); 
the second took place, for three months, at the Department of Biochemistry and 
Molecular Biophysics in Washington University School of Medicine in Saint Louis 
(MO, USA), under the supervision of Prof. Garland R. Marshall, investigating the 
activity profile of new Histone Deacetylases (HDACs) inhibitors by the application 
of the Mobility Shift Assay Technology.  
Main purpose of this doctoral thesis is to highlight the activities carried out in the 
different research projects, the applied methodologies and the obtained results. The 
vi 
 
text starts describing those studies whose results were published in scientific 
journals (chapters I-VI): the author decided to omit some procedural details, 
completely reported in the published papers, that would make the text too long, 
tedious and redundant; therefore readers who want to delve these aspects can also 
refer to Chapter XII in which is possible to read the original papers; on the contrary 
for studies that have not yet been published, as those characterizing the Chapters 
VII and VIII, discussion is adequately detailed. Chapters IX and X report the 
scientific activities carried out in France and in USA respectively; Chapter XI 
summarizes all the scientific activities accomplished during the entire PhD course, 
whereas Chapter XII, as mentioned, contains the published articles.  
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Chapter I 
3-D QSAutogrid/R: An alternative procedure to build 3-D QSAR models. 
Methodologies and applications 
Flavio Ballante and Rino Ragno 
Journal of Chemical Information and Modeling 2012 52 (6), 1674-1685 
Preamble 
This chapter refers to a work that I care particularly, a constantly evolving project 
which began few years ago: the 3-D QSAutogrid/R procedure.
1
 The 3-D 
QSAutogrid/R is a tool, designed and developed to be freely used from academics, 
capable to perform optimized three dimensional quantitative structure-activity 
relationship (3-D QSAR) studies by the means of the PLS algorithm
2
. Respect to 
the classic 3-D QSAR approaches (like CoMFA
3
 and GRID
4
/GOLPE
5
) allows to: 
 minimize human-machine interactions, costs, and calculation time 
 select the most appropriate pretreatment parameters (CAPP1 procedure) 
 conduct MPGRS1 (Multi Probe Guided Region Selection) analyses 
 
The 3-D QSAutogrid/R procedure is, actually, the default 3-D QSAR methodology 
used at the Rome Center for Molecular Design laboratory (RCMD, Department of 
Chemistry and Drug Technologies Sapienza University of Rome), and the core 
engine to prepare thousands of 3-D QSAR models, based on either ligand based 
(LB) or structure based (SB) alignment methodologies, forming the very first 3-D 
QSAR server (www.3d-qsar.com), which allows to model the desired ligand and to 
retrieve the predicted biological affinity for the chosen model. Several studies,
6-10
 
characterizing my PhD scholarship, were accomplished using this procedure 
confirming its usefulness in drug discovery.   
2 
 
The Procedure 
The 3-D QSAutogrid/R methodology
1
 is based on the integration of the molecular 
interaction fields (MIFs) as calculated by the AutoGrid program (Autodock 
Suite
11
) and the R statistical environment,
12
 a freely available language for 
statistical computing and graphics. The AutoGrid software (based on the AMBER 
united-atom Force Field) is used to generate either training and test sets’ MIFs: in 
particular 8 different probes (Table 1) were chosen in agreement with the most 
common residue atomic composition, and currently implemented.  
 
Table 1. List of the AutoGrid probes employed for MIF calculation. 
Probe Type Description 
A Aromatic Carbon 
C Aliphatic (sp
3
) Carbon 
OA Hydrogen-bond-accepting oxygen 
HD Hydrogen bonded to heteroatom 
NA Hydrogen-bond-accepting amine nitrogen 
N Amide nitrogen 
e Electrostatic 
d Desolvation 
 
Several R-based packages (Table 2, Figure 1) were developed to carry out 
complete 3-D QSAR studies to obtain a comprehensive statistical and graphical 
report (see Computational methods section) for each different used probe and 
principal component (PC). The procedure needs only the pre-aligned training and 
test sets molecules. 
What makes the 3-D QSAutogrid/R procedure innovative is the capability to 
determine, through a combinatorial calculation (CAPP procedure),
1
 the most 
appropriate pretreatment values to get optimized 3-D QSAR models; but especially 
the possibility to derive multiprobe 3-D QSAR models (MPGRS procedure)
1
 
3 
 
highlighting the most informative regions around the ligands, using all the probes 
together, and reducing the chance of missing important correlations when using 
single probe 3-D QSARs. 
The whole procedure was validated on three data sets, covering both ligand-based 
(LB) and structure-based (SB) alignment methodologies, previously reported using 
CoMFA
13
 and GRID/GOLPE,
14
 respectively. 
 
Table 2. List of the R compiled packages. 
R package Description 
D2M Data to Model 
CAPP Combinatorial Analysis of Pretreatment Parameters 
MDP Model Data Pretreatment 
CV Cross Validation 
VS Variable Selection 
GRS Guided Region Selection 
MPGRS Multi Probe Guided Region Selection 
ESP External Set Prediction 
YS Y-scrambling 
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Figure 1. 3-D QSAutogrid/R process workflow. Acronyms inside the blue meshed 
square refer to the packages (steps) that effectively build or optimize the statistical 
PLS 3-DQSAR models; others are related to packages that perform analysis on 
these created models (see below for the description of each package). D2M: “Data 
to Model”; CAPP: “Combinatorial Analysis of Pretreatment Parameters”; MDP: 
“Model Data Pretreatment”; CV: “Cross-Validation”; VS: “Variable Selection”; 
(MP)GRS: “(Multi Probe) Guided Region Selection”; ESP: “External Set 
Prediction”; YS: Y-scrambling. 
 
Computational Methods 
As reported,
1
 each R-package is able to perform a specific 3-D QSAR analysis 
process releasing all the statistical and graphical results (Figure 2):  
1) D2M package (“Data to Model”): allows to import the training set biological 
data and MIF information (even MIFs generated with different tools, i.e. 
GRID or CoMFA) to build a raw PLS 3-D QSAR model for each used probe 
and user-defined principal component (PC).  
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Figure 2. Overview of the information released by the 3-D QSAutogrid/R 
procedure. 
6 
 
2) CV package (“Cross Validation”): allows to perform different kind of 
internal validation methods like LOO (leave one-out), LSO (leave-some-
out), KF (k-fold), and MC (Monte Carlo) to: 
 assess the chance correlation;15 
 select the optimal model dimensionality (number of PCs); 
 measure the internal predictive ability by means of statistical 
coefficients such as cross-validated correlation coefficient (q
2
) and 
standard deviation error of prediction (SDEP); 
3) CAPP package (“Combinatorial Analysis of Pretreatment Parameters”): 
represents a new 3-D QSAR feature, since it systematically seek the more 
efficient data pretreatment values (energy cutoff, zeroing of very low data 
points, and minimum standard deviation cutoff) through a combinatorial 
analysis: for each combination the pre-treated model is generated and then 
its q
2
 evaluated using LOOCV, LSOCV or KFCV. The optimal pretreatment 
combination is then selected according to the maximum q
2
 and the 
percentage decrement of sPRESS values between subsequent PCs.
16
 
4) MDP package (“Model Data Pretreatment”): to pretreat the molecular 
descriptors (MIFs), in an arbitrary way or as found by the CAPP procedure. 
A further data filter, that performs the 1N kind of 2-level variable 
elimination (variables which take only 2 values in all of the data file, one of 
which appears only in one object) can be selected.  
5) VS package (“Variable Selection”) allows to reduce redundant data 
improving the predictability of the statistical model. Different variable-
selection algorithms are implemented as: genetic algorithm
17
 (GA), 
simulated annealing
18
 (SA) and fractional factorial design
19
 (FFD). 
6) GRS package (“q2-Guided Region Selection): this package, inspired on the 
previously reported q
2
-guided region selection (q
2
-GRS)
20
 and smart-region 
7 
 
definition
20, 21
 (SRD),
20, 21
 allows to extract, for each probe and PC, only 
those sub-areas endowed with a q
2
 value greater than a specified threshold. 
7) MPGRS package (“Multi Probe Guided Region Selection”): the MPGRS 
approach is a new powerful tool capable to conduct advanced 3-D QSAR 
analyses. Indeed, this procedure is able to sum all the most defining 
chemical information, obtained by all the mono-probe models, deriving  
final quantitative pharmacophoric models. 
8) YS package (Y-Scrambling): this package allows to detect if the 3-D QSAR 
model is characterized by chance correlation
15
 by means of scrambling 
procedure22 
9) ESP package (External Set Prediction): this tool is of fundamental 
importance, in fact: 1) allows to test the predictive capability of the 3-D 
QSAR models against an external test set of molecules with known 
biological responses; 2) predicts the activity of untested or not yet 
synthetized compounds. 
 
Results and discussion 
The procedure was validated
1
 on three data sets, covering both ligand-based and 
structure-based alignment methodologies: 
• a data set of aligned opioid-receptor antagonists (LB data set)13 
• two data sets of Hepatitis C Virus NS5B-Polymerase Inhibitors (SB data sets)14  
LB data set (opioid-receptor antagonists): 
A data set composed of 74 pre-aligned compounds with associated δ, µ, κ opioid-
binding affinities, previously described in a CoMFA application,
13
 was used to 
build 24 3-D QSAR models with the new procedure, maintaining the original
13
 
training set and test set composition. All the 3-D QSARs were built, pretreated 
8 
 
through the CAPP procedure, and optimized by means of the genetic algorithm 
(GA, package VS). All the models were cross-validated through Leave-One-Out 
(LOO), Leave-Two-Out (LTO), k-Fold (KF) and Monte Carlo (MC) 
methodologies and submitted to the YS package to test the presence of chance 
correlation. To directly compare the two methodologies, double probe models 
(DP), similarly to those generated by CoMFA, were built. Statistical results 
(Tables 3 and 4), were similar to those originally obtained (compare Tables 3 and 4 
with table 5), confirming the robustness of the methodology. Moreover, the 
obtained contour maps were in agreement with those obtained from CoMFA. As 
for example, activity contribution plots obtained from the δ DP models are shown 
(compare Figures 3 and 4 with Figures 5 and 6). 
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Table 3. Opioid-receptor antagonists: Autogrid/R PLS models statistical results 
(CAPP and GA processes were applied). 
model OR P PC r
2
 q
2
LOO q
2
K5FCV r
2
YS q
2
YS 
1 δ A 2 0.81 0.73 0.70 0.27 -0.37 
2 δ C 2 0.82 0.74 0.71 0.32 -0.35 
3 δ HD 2 0.83 0.75 0.72 0.33 -0.34 
4 δ NA 2 0.83 0.75 0.73 0.31 -0.34 
5 δ N 2 0.83 0.76 0.72 0.29 -0.32 
6 δ OA 2 0.83 0.74 0.71 0.32 -0.37 
7 δ e 3 0.69 0.58 0.56 0.22 -0.19 
8 δ d 3 0.70 0.59 0.55 0.24 -0.30 
9 μ A 3 0.91 0.82 0.76 0.57 -0.50 
10 μ C 3 0.90 0.81 0.78 0.59 -0.50 
11 μ HD 3 0.90 0.81 0.75 0.47 -0.49 
12 μ NA 3 0.91 0.81 0.78 0.59 -0.50 
13 μ N 3 0.91 0.83 0.78 0.52 -0.61 
14 μ OA 3 0.91 0.83 0.77 0.51 -0.61 
15 μ e
a
 1 0.31 0.21 0.20 0.06 -0.10 
16 μ d 3 0.72 0.60 0.52 0.27 -0.39 
17 κ A 2 0.78 0.58 0.49 0.42 -0.37 
18 κ C 3 0.81 0.62 0.55 0.54 -0.53 
19 κ HD 3 0.82 0.72 0.65 0.34 -0.41 
20 κ NA 3 0.80 0.62 0.54 0.55 -0.47 
21 κ N 3 0.80 0.61 0.52 0.54 -0.48 
22 κ OA 3 0.82 0.65 0.59 0.54 -0.44 
23 κ e
a
 2 0.35 0.20 0.18 0.13 -0.18 
24 κ d 3 0.58 0.38 0.34 0.29 -0.36 
OR: Opioid-receptor data, P:Autogrid Probe, PC: optimal number of principal 
components/latent variables, r
2
: conventional square-correlation coefficient; q
2
LOO: 
cross-validation correlation coefficient using the leave-one-out method; q
2
K5FCV: 
cross-validation correlation coefficient using the k-fold cross-validation with 5 
random groups and 100 iterations; r
2
YS: average square correlation coefficient 
obtained after Y-scrambling process using 100 iterations; q
2
YS: average cross-
validation correlation coefficient using the leave-one-out method obtained after Y-
scrambling process using 100 iterations 
a
The e models 15 and 23 reported were 
only pretreated due to too few variables after GA selection. 
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Table 4. Opioid-receptor antagonists: Autogrid double-probe (DP) PLS models 
statistical results (only the CAPP process was applied). 
model OR P PC r
2
 q
2
LOO q
2
K5FCV r
2
YS q
2
YS 
28 δ Autogrid DP 3 0.83 0.70 0.67 0.41 -0.50 
29 μ Autogrid DP 4 0.85 0.65 0.63 0.52 -0.53 
30 κ Autogrid DP 3 0.84 0.67 0.63 0.50 -0.53 
OR: Opioid-receptor data; P: Autogrid double probe (DP, C and e probes), PC: 
optimal number of principal components/latent variables, r
2
: conventional square-
correlation coefficient; q
2
LOO: cross-validation correlation coefficient using the 
leave-one-out method; q
2
K5FCV: cross-validation correlation coefficient using the k-
fold cross-validation with 5 random groups and 100 iterations; r
2
YS: average square 
correlation coefficient obtained after Y-scrambling process using 100 iterations; 
q
2
YS: average cross-validation correlation coefficient using the leave-one-out 
method obtained after Y-scrambling process using 100 iterations 
 
 
Table 5. Opioid-receptor antagonists: original CoMFA models statistical results. 
model OR P PC r
2
 q
2
LOO q
2
K5FCV 
25 δ CoMFA 4 0.91 0.69 - 
26 μ CoMFA 4 0.92 0.67 - 
27 κ CoMFA 6 0.96 0.60 - 
OR: Opioid-receptor data; P: standard CoMFA Probe Csp3
+
, PC: optimal number 
of principal components/latent variables, r
2
: conventional square-correlation 
coefficient; q
2
LOO: cross-validation correlation coefficient using the leave-one-
out method; q
2
K5FCV: cross-validation correlation coefficient using the k-fold 
cross-validation with 5 random groups and 100 iterations. 
 
By means of the ESP package,
1
 all the 3-D QSAutogrid/R models were externally 
validated, as in the original CoMFA application,
13
 confirming the robustness of the 
methodology even in predicting the external test sets (compare Table 6 with Table 
7). 
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A B 
Figure 3. CoMFA-like steric-contour map derived from the C probe for the δ-
opioid receptors. A: compounds 18 (sky blue), 20 (white), 22 (green), 50 (purple) 
and 67 (red). B: compounds 30 (brown) and 68 (pink). Contour levels: 85% 
(positive green, negative yellow). Hydrogen atoms are omitted for the sake of 
clarity. In A and B are reported similar contour maps for the new procedure and 
CoMFA. 
 
 
 
Figure 4. CoMFA-like electrostatic contour map derived from e probe for the δ-
opioid receptors. Compounds: Naltrexone in magenta, NTI in yellow, 24 in green. 
Contour levels: 85% (positive blue, negative red). Hydrogen atoms are omitted for 
clarity. 
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A B 
Figure 5. CoMFA steric contour map for the δ opioid receptors. A: compound 18 
in sky blue, 20 in white, 22 in green, 50 in purple and 67 in red. B: compound 30 in 
brown, 68 in pink. Green (favored): 80%, yellow (disfavored) 20%. Hydrogen 
atoms are omitted for the sake of clarity. 
 
Figure 6. CoMFA electrostatic contour map for the δ opioid receptors. Naltrexone 
in magenta, NTI yellow, 24 green, Blue favored 80%, red (disfavored) 20%. 
Hydrogen atoms are omitted for the sake of clarity. 
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Table 6. δ Test Set predictions indicated by SDEP values. 
OR Model P PC SDEPTS1 SDEPTS2 
1 A 2 0.66 0.80 
2 C 2 0.64 0.77 
3 HD 2 0.62 0.74 
4 NA 2 0.64 0.82 
5 N 2 0.64 0.76 
6 OA 2 0.65 0.75 
7 e 3 0.81 1.20 
8 d 3 0.90 1.12 
OR Model: Opioid-receptor model of Table 6; P: Autogrid probe, PC: 
optimal number of principal components/latent variables; SDEPTS1: standard 
deviation error of prediction for the original test set; SDEPTS2: standard 
deviation error of prediction for the external test set. 
 
 
A 
 
 pKi  pKi 
compd exptl pred res compd exptl pred red 
6 7.1 7.98 -0.88 42 6.29 7.23 -0.94 
11 8.33 8.33 0.00 47 9.11 8.09 1.02 
13 7.28 7.23 0.05 48 8.75 8.25 0.5 
19 7.74 8.47 -0.73 52 6.90 6.77 0.13 
27 7.15 7.43 -0.28 64 7.80 8.28 -0.48 
37 7.66 8.31 -0.65 70 5.62 6.37 -0.75 
39 8.05 8.81 -0.76   
B 
 
 
Table 7. Opioid receptor antagonists: Experimental and Predicted pKi values of 
the δ Test Set compounds; A: CoMFA values from the reference,13 experimental 
activity for compd 27 was mistyped, the right one is equal to 7.15; B: AutoGrid/R 
δ CAPP pretreated double probe (DP) model values.  
14 
 
SB data set (Hepatitis C Virus NS5B-Polymerase Inhibitors): 
In this application two structure based datasets composed of HCV NS5B non-
nucleoside inhibitors (thumb and palm NNI), previously investigated
14
 through the 
GRID/GOLPE methodology,
5
 were submitted to the 3-DQSAutogrid/R protocol.
1
 
As for the LB study, the models were built, and optimized via the CAPP 
procedure. Since no variable selection was originally applied,
14
 no further 
optimization processes were performed on the models. As for the LB case study, 
the 3-DQSAutogrid/R procedure proved to derive models comparable to those 
originally reported
14
 concerning either the statistical (Table 8) and graphical 
results. In this case was decided to show the similarities between the PLS-
coefficients plots obtained from the two methodologies (Figure 7). 
 
 
 
  
A B 
Figure 7. PLS-coefficients contour maps using the thumb-training set; only the 
highest active (6 in cyan) and one of the lowest active (11 in orange) compounds 
are shown. A: AutoGrid/R PLS coefficients contour maps derived from A probe 
analysis (Contour levels: 60%, positive red, negative blue). B: GRID/GOLPE PLS 
coefficients contour maps derived from C1= GRID probe analysis (contour levels: 
0.0008 red, -0.0008 blue).  
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Table 8. PLS Analysis Results for the Thumb- and the Palm-Structure Based 
Autogrid/R and original GRID/GOLPE C1= 3-D QSAR Models. 
Dataset P PC r
2
 q
2
LOO q
2
K5FCV r
2
YS q
2
YS 
Thumb A 2 0.90 0.67 0.64 0.70 -0.63 
Thumb C 2 0.90 0.68 0.65 0.70 -0.60 
Thumb HD 2 0.92 0.75 0.73 0.68 -0.69 
Thumb NA 3 0.95 0.75 0.73 0.79 -0.66 
Thumb N 3 0.95 0.76 0.73 0.78 -0.67 
Thumb OA 3 0.95 0.77 0.73 0.77 -0.54 
Thumb e 3 0.98 0.58 0.52 0.92 -0.55 
Thumb d 1 0.58 0.36 0.36 0.27 -0.38 
Thumb GRID/GOLPE/C1= 3 0.99 - 0.69 - - 
Palm A 3 0.96 0.73 0.62 0.68 -1.62 
Palm C 3 0.96 0.73 0.62 0.69 -1.59 
Palm HD 1 0.90 0.75 0.71 0.44 -0.76 
Palm NA 2 0.97 0.62 0.52 0.84 -0.76 
Palm N 2 0.97 0.62 0.55 0.85 -0.87 
Palm OA 1 0.86 0.67 0.64 0.32 -0.66 
Palm e 3 0.96 0.85 0.82 0.73 -1.01 
Palm d 3 0.93 0.62 0.39 0.73 -1.80 
Palm GRID/GOLPE/C1= 3 0.99 - 0.55 - - 
P:Autogrid Probe or GRID C1= probe; PC: optimal number of principal 
components/latent variables, r
2
: conventional square-correlation coefficient; q
2
LOO: 
cross-validation correlation coefficient using the leave-one-out method; q
2
K5FCV: 
cross-validation correlation coefficient using the k-fold cross-validation with 5 
random groups and 100 iterations; r
2
YS: average square correlation coefficient 
obtained after Y-scrambling process using 100 iterations; q
2
YS: average cross-
validation correlation coefficient using the leave-one-out method obtained after Y-
scrambling process using 100 iterations. 
 
 
As for the original application,
14
 all the 3-DQSAR models were then externally 
tested, showing statistical values comparable with those obtained
14
 applying the 
GRID/GOLPE approach (Table 9). 
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Table 9. Thumb- and Palm-External Test Set prediction obtained from Structure 
Based AutoGrid/R and original GRID/GOLPE C1= 3-D QSAR Models. 
Dataset P PC SDEPext 
Thumb A 2 0.69 
Thumb C 2 0.69 
Thumb HD 2 0.76 
Thumb NA 3 0.66 
Thumb N 3 0.66 
Thumb OA 3 0.67 
Thumb e 3 0.63 
Thumb d 1 0.67 
Thumb GRID/GOLPE/C1= 3 0.59 
Palm A 3 1.14 
Palm C 3 1.11 
Palm HD 1 1.29 
Palm NA 2 1.04 
Palm N 2 1.04 
Palm OA 1 1.03 
Palm e 3 1.18 
Palm d 3 1.18 
Palm GRID/GOLPE/C1= 3 1.08 
P:Autogrid Probe or GRID C1=probe; PC: optimal number of principal 
components/latent variables; SDEPext: standard deviation error of prediction for the 
external test set. 
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Multi-Probe Guided Region-Variable Selection 
The Multi Probe Guided Region Selection methodology (MPGRS), represents a 
new powerful technique able to condense all the most informative interactions 
(from the mono probe models) in a single 3-D QSAR PLS model, leading to more 
comprehensive interpretations and allowing to derive useful three-dimensional 
pharmacophoric quantitative models (as explained in Chapters VI and VII). As 
reported,
1
 each probe information is color coded according to Table 10. To test the 
procedure, the MPGRS was applied to both the case studies  (LB and SB). All the 
multiprobe models (MP) were characterized by similar statistical coefficients as 
those obtained from the mono probe models (to avoid redundancy only the results 
from the SB case study are reported, Table 11) but enhancing the interpretation of 
the models (as in other studies like those characterizing Chapters VI and VII). 
 
Table 10. List of the AutoGrid probes employed for MIF calculation and MPGRS 
Subregion color coding. 
Probe Description MPGRS Colour 
A Aromatic Carbon Gray 
C Aliphatic (sp
3
) Carbon Dark Gray 
HD Hydrogen bonded to heteroatom Green 
NA Hydrogen-bond-accepting amine nitrogen Cyan 
N Amide nitrogen Blue 
OA Hydrogen-bond-accepting oxygen Red 
e Electrostatic Orange 
d Desolvation Yellow 
 
 
It was very interesting to overlap the information obtained from multiprobe models 
built for the SB case study, with the SB alignments, in order to compare the 
proposed pseudo receptor with experimental information. As for example, Figure 8 
shows the pharmacophoric model (key interactions) derived from the multiprobe 
palm model. An high agreement between the selected regions and the HCV NS5B-
palm binding pocket surface was observed,
1
 demonstrating the usefulness of this 
application. More specific analyses can be developed using either these 
informative interactions with the associated PLS-coefficients (as applied during the 
studies characterizing Chapters VI and VII). 
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Table 11. Statistical Results Obtained from MPGRS Analysis for the Thumb- and 
the Palm-HCV Training Sets. 
MPGRS 3-D QSAR 
Dataset PCFL:SL r
2
 q
2
K5FCV r
2
YS q
2
YS SDEPext 
Thumb 2:2 0.95 0.90 0.50 -0.67 0.74 
Palm 1:2 0.99 0.91 0.61 -0.93 1.06 
PCFL:SL: optimal number of principal first level (FL) and second level (SL) 
components/latent variables for the MPGRS model; r
2
: conventional square-
correlation coefficient; q
2
LOO: cross-validation correlation coefficient using the 
leave-one-out method; q
2
K5FCV: cross-validation correlation coefficient using the k-
fold cross-validation with 5 random groups and 100 iterations; r
2
YS: average square 
correlation coefficient obtained after Y-scrambling process using 100 iterations; 
q
2
YS: average cross-validation correlation coefficient using the leave-one-out 
method obtained after Y-scrambling process using 100 iterations. 
 
 
 
Figure 8. MPGRS 3-D QSAR palm model key points. The points are color coded: 
in blue N (amidic nitrogen) probe key points, in cyan those from NA (hydrogen 
acceptor nitrogen) probe, in green and orange those from HD (hydrogen donator) 
and e (electrostatic) probes respectively. 
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Chapter II 
Comprehensive model of wild-type and mutant HIV-1 reverse transciptases 
Flavio Ballante, Ira Musmuca, Garland R. Marshall, Rino Ragno 
Journal of Computer-Aided Molecular Design. 2012 Aug;26(8):907-19. 
 
Preamble 
This study is characterized by the application of the COMBINEr procedure,
1
 
developed by us, to obtain a comprehensive 3-D QSAR model of 7 different HIV-1 
reverse transcriptase enzymes (RT, wild-type and drug-resistant mutants) 
complexed with niverapine (NVP) and efavirenz (EFV), able to define those 
mutations responsible for the different activity profiles. The model predictive 
ability was assessed using an external test set of novel chiral 2-(alkyl/aryl)amino-
6-benzylpyrimidin-4(3H)-ones (DABOs).
2
 The COMBINEr model was able to 
correctly predict either the experimental activities and the right eudismic ratio of 
the test set derivatives, rationalizing the experimentally observed inhibitory 
activity and confirming to be a useful tool in drug discovery. 
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Figure 1. Computational procedure. 
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Introduction 
The COMBINEr procedure,
1, 3
 an enhanced version of the original COMBINE 
methodology,
4-6
 is a structure based (SB) 3-D QSAR application that uses ligand-
receptor complexes to quantify, by molecular mechanics, their interaction 
energies.
7
 The novelty of COMBINEr is to use the AutoGrid program 
(AutoDockTools)
8
 to calculate ligand-residues interaction energies for each ligand-
enzyme complex and derive, through the PLS
9, 10
 multivariate analysis, descriptive 
and predictive models through the R environment.
11
 Since its capability to direct 
compute the ligand/enzyme per residue interaction it represents a powerful tool to 
highlight the most important ligand-receptor interactions explaining the effect of 
single points mutation, on the ligands’ inhibitory activity, as in the case of the 
HIV-1 reverse transcriptase (RT) mutant enzymes that characterize the application 
characterizing this chapter. 
 
Applied Methodology 
The choice of the training set was based considering both the availability of 
homogeneous inhibition data
2
 for Nevirapine (NVP) and Efavirenz (EFV) (Figure 
A1), and co-crystal structures. This approach, led to the selection of 7 different 
HIV-RT wild-type and mutant enzymes complexed with the two inhibitors 
(Appendix A Table A1). Therefore, a total of 14 complexes composed the training 
set: since co-crystal structures were available for only five complexes, the other 
nine were modeled using as template structural information available from other 
complexes present in the PDB.
3
 As reported,
3
 a superimposition/minimization 
protocol was then applied to get these complexes ready for the COMBINEr
1
 
investigation. By means of Autogrid4,
8
 three kinds of ligand/residue interactions: 
the electrostatic (ELE), the steric (STE) and the desolvation (DRY) were derived 
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for each complex to compose seven different fields combinations: the monoprobe 
fields (DRY, ELE and STE) and the multiprobe fields (DRY+STE, ELE+STE, 
DRY+ELE, and DRY+ELE+STE), and derive, finally, seven different COMBINEr 
PLS
10
 models (CM1-CM7, Table 1). As shown in Table 1, all these models were 
characterized by good statistical coefficients, but only two, CM1 and CM4 
(showing the best statistical-values profiles), were selected for further 
investigations. PLS coefficients, weighted PLS coefficients (PLS coefficients x 
standard deviation values) and activity contribution plots (PLS coefficients x 
interaction energies), were of fundamental importance to detect which residues are 
relevant for differences in activity and quantify their relative importance. By 
analyzing these plots, has appeared how a similar profile was characterizing the 
DRY field in both CM1 and CM4 models,
3
 therefore the attention was focused on 
the latter (DRY+STE fields) in order to consider more data. Analyses of PLS 
coefficients allowed to identify the residues mainly involved in the model 
definition
3
 (Figure 2) while weighted PLS coefficients (Figure 3) were useful to 
derive the global importance of each interaction. Results of these investigations 
suggested that interactions with residues Leu100(Ile100), Lys101 and Tyr188 
(Leu188) are desirable, while should be avoided with residues Trp229 and Leu224 
(Figures 2 and 3). 
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Table 1. Statistical coefficients of the COMBINE models. CM: COMBINE Model 
Number; r
2
: conventional squared correlation coefficient; SDEC: standard error of 
calculation; q
2
: cross-validation coefficient; LOO: leave one out; SDEP: standard 
error of prediction; LSO5 and LSO2: leave some out using 5 and 2 groups 
respectively. 
CM Model r
2
 SDEC q
2
LOO SDEPLOO q
2
LSO5 SDEPLSO5 q
2
LSO2 SDEPLSO2 
1 DRY 0.91 0.31 0.82 0.43 0.79 0.46 0.63 0.58 
2 ELE 0.80 0.45 0.51 0.71 0.49 0.72 0.37 0.79 
3 STE 0.81 0.44 0.69 0.57 0.65 0.60 0.52 0.68 
4 DRY_STE 0.88 0.35 0.78 0.48 0.75 0.50 0.61 0.61 
5 ELE_STE 0.82 0.43 0.58 0.66 0.53 0.69 0.44 0.75 
6 DRY_ELE 0.89 0.34 0.66 0.59 0.63 0.62 0.48 0.70 
7 DRY_ELE_STE 0.86 0.38 0.66 0.59 0.62 0.62 0.50 0.70 
 
 
 
Figure 2. PLS coefficients obtained from the CM4 model. Only bars with values 
higher than 0.001 and lower than -0.001 are shown. 
 
26 
 
 
Figure 3. PLS coefficients x SD obtained from the CM4 model. Only bars with 
values higher than 0.001 and lower than -0.001 are shown. 
 
The CM4 model was finally applied to an external test set composed of four 
DABO derivatives
2
 (Appendix A Figure A2) with the purpose to rationalize the 
role of the mutations on their activity profile. To build the non-experimental 
complexes, with those isoforms used to test these compounds,
2
 a reported
12
 cross-
docking protocol was applied by means of the AutoDockVina.
13
 This docking 
program was chosen after a docking assessment investigation in which either 
AutodockVina
13
 and AutoDock
8
 were tested for their reliability.
3
 Binding mode 
analyses suggested similar poses for R-conformations of MC-1501 and MC2082, 
in agreement with previous studies,
14-16
 while for (S) derivatives, results confirmed 
the role of the methyl group at the C6-benzylic position to prevent similar 
interactions.
16
 The COMBINEr
1
 model was able to predict with an acceptable 
average absolute error of prediction the test set experimental activities (Table 2), 
tracing the right eudismic ratio for the two R/S pairs. As extensively reported in the 
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paper,
3
 straightforward was the possibility to investigate the activity contributions 
(Figure 4) of each inhibitor/residue couple, allowing to: 
a) confirm that the residues mutations were responsible for the different 
activity profiles of EFV and NVP  
b)  derive a final three-dimensional scheme of contributions for each 
inhibitor/residue pair (Figure 5) 
c) identify what interactions determine the different activity profiles: 
 interaction with Lys101 was identified, from both DRY and STE 
fields analysis, to be the mainly responsible for the higher activity of 
(R)-MC2082 respect (R)-MC1501; 
 DRY and STE interactions with Trp229 and Lys101 respectively, 
contribute for the higher activity of (R)-MC1501 versus (S)- MC1501 
 Lys101 and Trp229 DRY interactions, and mostly Lys101 STE 
interaction, determine the higher activity of (R)-MC2082 respect (S)-
MC2082; 
 residue 188 is capable to maintain interactions with ligands in its 
wild-type (Tyr188) and in the Leu188 mutation, and to compensate 
for loss of activities due to other single-point mutations. 
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Figure 4. Activity contribution histograms obtained from the CM4 model. Only 
bars with values higher than 0.001 and lower than -0.001 are shown. 
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 EFV NVP 
A 
(+90 °) 
  
B 
Frontal 
View 
 
 
C 
(-90 °) 
 
 
 
  
Figure 5. Efavirenz (EFV) and Nevirapine (NVP) with the surrounding 
residues surfaces as in the experimental complexes. The surfaces are colored 
by activity contribution. Three view of the complexes which are rotated 
along the X axes by ±90 ° are shown. 
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Table 2. Experimental and COMBINE model CM4 predicted activities of MC 
compounds.  
 MC1501 MC2082 
R S R S 
Exp Pred Exp Pred Exp Pred Exp Pred 
WT 8.70 7.46 6.93 7.20 6.81 7.21 4.52 5.77 
V106A 8.52 9.19 6.45 5.78 9.52 9.43 6.62 7.51 
K103N 7.02 7.17 6.01 7.52 8.52 9.11 7.19 7.52 
L100I 7.02 6.69 4.40 7.11 8.10 7.49 6.74 6.03 
Y188L 6.71 7.51 4.40 5.11 8.10 7.09 4.40 5.95 
Y181I 6.35 6.05 4.40 6.12 6.12 6.25 6.29 5.48 
 
  
31 
 
APPENDIX A 
Table A1. Anti-RT activities (µM) of NVP and EFV used to build the COMBINEr 
model. 
RT NVP EFV 
WT 0.4 0.03 
L100I 9.0 0.12 
K103N 7.0 0.16 
V106A 10.0 0.04 
V179D 2.0 0.10 
Y181I 36.0 0.15 
Y188L 18.0 0.38 
 
 
Nevirapine (NVP) Efavirenz (EFV) 
  
Figure A1. Nevirapine and Efavirenz.  
 
 
(R/S) MC1501 
(N,N-DABO) 
(R/S) MC2082 
(DAPY-DABO Hybrid) 
 
 
Figure A2. Racemic DABO derivatives used as external test set.   
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Chapter III 
2-(Alkyl/Aryl)amino-6-benzylpyrimidin-4(3 H)-ones as inhibitors of wild-type 
and mutant HIV-1: Enantioselectivity studies 
Dante Rotili, Alberta Samuele, Domenico Tarantino, Rino Ragno, Ira Musmuca, 
Flavio Ballante, Giorgia Botta, Ludovica Morera, Marco Pierini, Roberto Cirilli, 
Maxim B. Nawrozkij, Emmanuel Gonzalez, Bonaventura Clotet, Marino Artico, 
José A. Esté, Giovanni Maga, and Antonello Mai 
Journal of Medicinal Chemistry 2012 55 (7), 3558-3562 
 
Preamble 
This study is strictly related with that characterizing Chapter II. In fact the 
COMBINEr CM4 model, previously developed, was used to predict the biological 
activity of two potent anti-HIV-1 derivatives: MC1501 and MC2082, which are the 
object of the present study, to quantify the influence of single-point HIV-RT 
mutations on their activity. As discussed in the previous Chapter, the COMBINEr 
methodology confirmed to be a useful tool to explain the role of single point 
mutations and predict the different activity profiles. 
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Introduction 
F2-N,N-DABO (MC1501)
1
 and DABO-DAPY (MC2082)
2
 are two pyrimidine-
based non-nucleoside reverse trascriptase (RT) inhibitors (NNRTI) endowed with 
high anti-HIV-1 activity and characterized by a stereogenic center at the C-6 
benzylic position (Figure 1). In this study, these two highly potent anti-HIV-1 
agents where systematically investigated for their enantioselective anti-HIV-1 
activity. The availability of such homogeneous biological results together with the 
protein X-ray informations allowed to quantify the influence of single point HIV-
1-RT mutations by means of the previously developed COMBINEr CM4 model.
3
 
 
(R/S) MC1501 
(N,N-DABO) 
(R/S) MC2082 
(DAPY-DABO Hybrid) 
 
 
Figure 1. Racemic N,N-DABO and DAPY-DABO Hybrid.  
 
Results and Discussion 
The single enantiomers and the corresponding racemic mixtures of MC1501 and 
MC2082 were tested to evaluate their anti-HIV activity against WT HIV-1 and 
clinically relevant HIV-1 mutant strains (K103N, L100, Y181I, V106A and 
Y188L); nevirapine (NVP), efavirenz  (EFV) and dapivirine (TMC210) were 
tested as reference drugs. Biological results highlighted that, all the R forms were 
the more active, followed by the racemic mixtures and lastly by the S forms. 
36 
 
Moreover (R)-MC2082 resulted to be generally (except for Y181C) more active 
than (R)-MC1501. Biological results allowed to define, for the tested compounds, 
the different activity profiles against the different HIV-1 isoforms. Due to the 
availability of protein structures, both MC1501 and MC2082 binding 
conformations were derived applying a reported
4
 cross-docking protocol and 
externally evaluated by the COMBINEr CM4 model (see Chapter II for further 
specifications), in order to better understand the role of the different enzyme 
mutations. As reported in Chapter II, the COMBINEr CM4 model was able to 
predict the higher activity of (R) enantiomers respect the respective (S) form as 
well as the higher potency of MC2082 respect MC1501, in agreement with the 
experimental results. Moreover was possible to highlight the role of Lys101, 
Trp229 and Tyr188 as described in Chapter II.  
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Histone deacetylase inhibitors: Structure-based modeling and isoform-
selectivity prediction 
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Preamble 
In the last decade, considerable interest has developed towards those phenomena, 
called epigenetics,
1
 capable of influencing gene expression, without changing the 
structure of DNA. Actually, epigenetics plays a role of primary importance in 
scientific research, due to the fact that different diseases are related with its 
dysregulation, which may be potentially rebalanced or prevented by the targeted 
use of chemical agents 
2, 3
 The zinc-dependent mammalian histone deacetylases 
(HDACs) are a family of proteins comprising 11 enzymes (isoforms), which are 
fundamental for tissue’s development and homeostasis. Considering the link 
between misregulated HDAC activity, carcinogenesis and other human diseases, 
the design of selective HDAC inhibitors for therapeutic treatment is mandatory, to 
develop less toxic drugs clarifying the biological role of these enzymes. This study 
was characterized by the application of the COMBINEr
4, 5
 procedure on a series of 
class I/II HDACs complexes. During the investigation both ligand based (LB) and 
structure based (SB) alignment were used, considering all the eleven human zinc-
based enzyme isoforms, to define the most influent chemical interactions for 
activity and isoform selectivity, allowing to rationalize the design of novel 
compounds endowed with both high potency and selectivity. Moreover, the 
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COMBINEr models represent a useful tool to predict the bioactive profile of a 
given molecule towards the 11 HDAC isoforms, helping in the selection and 
development of new selective inhibitors. Due to the complexity, the 
comprehensiveness and the amount of used data characterizing this work, it is 
impossible to summarize all the aspects and results in a way different from that 
published by us. Therefore, the reader may refer to the next paragraph 
(Introduction on HDACs) and then directly to the scientific publication (Chapter 
XII).  
 
Introduction on HDACs 
A fundamental epigenetic mechanism is represented by chromatin remodeling, 
which appears to be controlled by the acetylation state of histone proteins (Figure 
1).
6
  
 
Figure 1. Histone proteins acetylation/deacetylation state is guaranteed by the 
activity of HATs and HDACs enzymes. 
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Two families of enzymes: histone deacetylase (HDAC) and histone acetyl 
transferase (HAT) are responsible to maintain the homeostatic acetylation state of 
histone proteins. In particular, histone deacetylases (HDACs) are a class of zinc 
metalloproteases that catalyze the deacetylation of acetylated histones by removing 
the acetyl moiety from the ɛ-amino groups of lysine residues in the N-terminal 
extensions of nucleosomal histones, causing transcriptional repression; on the 
contrary histone acetyl transferases (HATs) catalyze the acetylation of histone tails 
determining transcriptional activation. Over the last years, it has been found that 
overexpression of histone deacetylases (HDACs) plays an important role in 
carcinogenesis and other diseases (i.e. development of HIV latency and Malaria)
7-
10
. Thus, HDAC inhibitors have emerged as new therapeutic agents for multiple 
human diseases. To date, there are 18 known isoforms, distinguished in 4 classes 
according to homology with yeast deacetylases, cellular localization and enzymatic 
activity.
11
 The eleven human zinc-dependent isoforms (Figure 2 shows the 
catalytic mechanism) of class I (HDAC-1, -2, -3, and -8), II (which includes class 
IIa: HDAC-4, -5, -7, and -9, and class IIb: HDAC-6 and -10) and IV (HDAC- 11) 
are mainly considered since their involvement in different diseases like: cancer, 
viral and parasitic infections, neurodegenerative diseases and inflammation. 
Therefore, is of considerable interest to obtain and optimize selective inhibitors to: 
1) further clarify the biological effect of the different isoforms, 2) achieve a 
targeted therapeutic effect, 3) reduce adverse reactions characterizing non-selective 
therapies. Currently, HDAC inhibitors ( HDACI ) are divided according to their 
chemical structure, as follows: short chain fatty acids, hydroxamic acids, 
benzamides, ketones and cyclic peptides. Currently all the HDACI share a 
common pharmacophore, characterized by three fundamental structural elements: 
1) a zinc binding group, 2) a capping group and 3) a linker domain group. This 
pharmacophore can be represented using as reference the structure of trichostatin 
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A
12
 (TSA, Figure 3), among the first identified HDACIs. The first HDAC 
inhibitors approved by FDA are: Merck’s Zolinza, vorinostat (SAHA) and 
Celgene’s Istodax romidepsin (Figure 4), currently used for the treatment of 
cutaneous T-cell lymphoma. However, other derivatives are in clinical trials for the 
ability to block cell proliferation, promote differentiation and induce apoptosis.
13
  
 
 
Figure 2. HDAC zinc-dependent catalytic mechanism. Highlighted in yellow and 
green are the acetylated substrate and the products.  
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Figure 3. Common HDACi pharmacophore, TSA is depicted. 
To date, unfortunately, most of the derived HDACIs are not capable to inhibit 
specifically the different HDAC isoforms. Therefore, a main challenge is to design 
new selective compounds with the aim to elucidate the functions of each isoform 
and apply new efficient and less toxic therapeutic treatments. 
  
SAHA Romidepsin 
Figure 4. Structure of SAHA and Romidepsin. 
 
The purpose of this study, was to build and validate a 3-D QSAR Stucture-Based 
(SB) model, using the COMBINEr
4, 5
 method (an enhanced version of the original 
comparative binding energy analysis, COMBINE)
14-17
 over the 11 HDAC isoforms 
able to detect the most discriminant chemical interactions among the different 
enzyme isoforms, and predict the activity/selectivity of new derivatives (see the 
relative article in Chapter XII).  
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Preamble 
The following study, is a clear example of how the integration of different chemical 
approaches could lead to the achievement of a new lead compound. By the 
application of Structure Based (SB) Three-Dimensional Quantitative Structure 
Activity relationships (3-D QSAR), molecular modeling, organic chemistry and 
biological investigations, it was possible to detect new VEGFR-2 (KDR) and 
human umbilical vein endothelial cell (HUVEC) proliferation inhibitors. My 
contribution to this study focused on the computational-chemistry investigation, 
mainly characterized by molecular docking simulations and 3-D QSAR analyses. 
Among the discovered compounds, 2f showed the highest inhibitory activity (at µM 
concentration) representing a new lead compound and therefore a starting point to 
obtain more active derivatives after chemical modifications. This perspective 
characterized my first research activity abroad in France (Chapter IX): where I’ve 
practiced organic synthesis to obtain new thieno [2,3-d] pyrimidinones derivatives 
as promising VEGFR-2 inhibitors.  
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Introduction 
Angiogenesis is the process of new blood vessels growth, creating new capillaries 
from existing vasculature. Angiogenic dys-regulation may be involved in various 
diseases development and progression including inflammation,
1
 tumor growth
2
 and 
metastasis.
3
 Among the different protagonists involved in this process, of particular 
importance are: 
1) the vascular endothelial growth factors (VEGFs):4, 5 VEGF-A (commonly 
named VEGF), VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and the 
Placental Growth Factor (PIGF); 
2) the VEGF tyrosine kinase receptors:6 VEGFR-1 (Flt-1), VEGFR-2 (KDR) 
and VEGFR-3 (Flt-4). 
So far, many molecules have been approved by FDA and many others are currently 
in clinical trials as anticancer agents, capable to block VEGF (like bevacizumab:
7
 a 
humanized monoclonal antibody) or inhibit VEGFRs (like sorafenib (BAY 43-
9006)
8
 and sunitinib (SU11248),
9
 Figure 1). Considering that the VEGFR-2 
receptor (kinase insert domain receptor, KDR) seems to play a key role in tumour 
angiogenesis,
10, 11
 the VEGF/VEGFR-2 pathway provides several opportunities by 
which small molecules can be used as inhibitors of endothelial proliferation and 
migration and thus as anticancer agents. 
12-14
 Considering the impact of tumor 
angiogenesis and the resistance mechanism to anti-angiogenic compounds, the 
development of new VEGFR-2 inhibitors is mandatory. This study is characterized 
by the discovery of new thienopyrimidines, as new class of VEGFR-2 inhibitors, 
through the application of a multidisciplinary approach (Figure 2) composed of by: 
1) 3-D QSAR studies 
2) Molecular modeling applications 
3) Organic chemistry 
4) Biological investigations 
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Computational studies were developed by means of a reported molecular docking 
protocol
15
 and previously developed Structure-Based (SB) 3-D QSAR models.
16
 
Molecular Docking allowed to predict the binding poses of compounds for which 
co-crystal structures were not available with the target protein. Previously 
developed 3-D QSAR models,
16
 characterized by a training set composed of co-
crystallized compounds in the ATP-binding site of KDR, were used as a tool 1) to 
represent three-dimensionally what kind of interactions should be increased, 
introduced or minimized; 2) to predict the activity of yet untested molecules. Thus, 
the combination of these two applications composed a useful computational 
protocol to develop new VEGFR-2 inhibitors.
17
 
  
 
Figure 1. Inhibition pathways of angiogenesis. 
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Figure 2. Overview of the multidisciplinary approach. 
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At the beginning of the study thirty-five compounds (4-38),
17
 characterized by 
thienopyrimidine, thiazolotriazine and selenolotriazine scaffolds, were chosen 
according to their structural similarities in comparison to the most common anti-
angiogenic compounds and then biologically assayed to determine their inhibitor 
potency against VEGFR-2. This set was submitted to a previously reported
15
 
molecular docking procedure and binding mode analyses were conducted 
highlighting that:  
1) all the compounds’ binding poses showed the characterizing scaffolds 
overlapped with the central benzimidazole moiety of the reference structure 
(PDB 2qu5); 
2) as a consequence of the previous statement, they bind preferentially in the 
first part of the binding site 
3) concerning thienopyrimidines, an increased steric hindrance seems to 
increase the ligand/VEGFR-2 interactions as for those derivatives 
characterized by the presence of a third fused cycle 
4) regarding thiazolotriazines, steric hindrance has a detrimental effect 
5) selenolotriazines showed binding modes similar to those of the 
thienopyrimidines 
For the four most active compounds (14, 30, 33, 55, Appendix A Table A1) we 
decided to perform a deeper binding mode analysis (Figure 3) revealing that: 
1) all the predicted poses established strong interactions with a specific region 
characterized by Val27, Ala45, Lys47, Val93, Val95, Leu164 and Phe176 
residues,  
2) the presence of a morpholino substituent, as in the case of compound 35 
(the least active compounds of this selected series) determines an 
overturning of the selenotriazine group.  
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The thirty-five compounds where then used as an external test set for the 
previously developed SB 3-D QSAR protocol.
16
 Although over-predictive, 3-D 
QSAR models proved their predictiveness, since compounds 4-38 were 
experimentally recognized with a certain rate of inhibition activity.
17
 Moreover, 
useful information were obtained, by superimposing the 3-D QSAR plots with the 
most active compound (30, Figure 4) suggesting that increasing the steric 
hindrance (i.e. by introducing further sterical groups into the ATP binding site), 
should enhance the inhibitory potency. Following the above indications new 
thienopyrimidines/thienotriazines (1-3, Appendix A Table A2) were designed and 
subjected to both molecular docking and 3-D QSAR simulations. 3-D QSARs 
predicted the new compounds’ activity in a range comprised between 0.01 and 0.1 
µM (Table 1). Since the 3-D QSAR models were over-predictive, taking into 
account the observed prediction errors for compounds 4-38, it was expected that 
the new derivatives were characterized, at least, by a submicromolar activity. 
Among these compound 2f was predicted, as the most active, to be in a low 
nanomolar range and particular attention was given to its binding mode (Figures 5 
and 6): which showed its ability to establish a greater network of steric 
interactions, especially at the entrance of the active site. Compounds 1-3 were then 
synthetized and biologically assayed, to detect their inhibitory activity against 
VEGFR-2, at 200uM fixed doses. Interestingly, as predicted by the 3-D QSARs, 2f 
resulted to be the most active compound (99.2% of inhibition) showing an IC50 
value equal to 2.25±0.1 µM. Moreover, the 2f-tartaric acid salt, was biological 
tested on endothelial cell tube formation induced by VEGF, resulting 
17
 to be more 
than Sunitinib. Binding mode analysis, suggested that more active compounds 
could be obtained by introducing further substituents on piperidine positions 3 and 
4 (Figure 7), in order to enhance the interactions with the ATP binding pocket. 
Design of new compounds, as new potential VEGFR-2 inhibitors, was then 
51 
 
performed obtaining a series of new molecules to be synthetized. Three of them 
were synthetized by myself at the Laboratoire d'Ingénierie et Moléculaire 
Pharmacologique Biochimie (LIMBP) of the Université de Lorraine Metz 
(France), directed by Prof. Gilbert Kirsch during my first research period abroad 
(see Chapter IX). 
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A 
  
B 
  
C 
  
D 
  
Figure 3.  Details of the binding for compounds 14 (A), 30 (B), 33 (C) and 35 (D). 
To the right are shown the ligand/VEGFR-2 interactions profile as obtained with 
the ligplot program. 
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Table 1.Experimental and Predicted pIC50 for compounds 1-3. 
# 
% inhibition 
@ 200 Ma 
 Predicted pIC50 by Probe 
IC50 M A C HD e 
1a 38.8±3.5  7.01 7.01 7.02 7.56 
1b n.t.b  6.90 6.90 6.80 7.30 
1c 1.7±0.1  6.88 6.88 7.03 7.14 
2a 5.7±0.4  6.69 6.70 6.99 7.66 
2b n.a.c  6.85 6.85 7.08 7.17 
2c 3.9±0.2  6.50 6.50 6.70 8.23 
2d 2.1±0.1  6.65 6.66 6.62 8.03 
2e n.a.c  6.68 6.68 7.02 7.60 
2f 99.2±3.9 2.25±0.1 8.12 8.13 8.28 7.15 
2g 52.6±3.7  7.96 7.96 7.87 7.87 
2h n.a.c  7.34 7.34 7.31 8.65 
2i 19.0±0.7  7.16 7.16 7.13 8.72 
2j n.a.c  6.57 6.57 6.72 7.17 
3a 35.2±2.8  6.90 6.91 7.16 7.43 
3b 40.9±2.8  6.11 6.10 6.22 7.54 
3c 52.0±3.6  6.74 6.73 6.74 7.66 
3d 73.4±6.5  6.30 6.30 6.46 7.51 
a
Values are means±SEM of two determinations carried out in triplicate. 
b
Not tested. 
cNot active. No inhibition was observed up to 200 μM of the test compound. 
 
  
54 
 
 
 
A 
 
 
B C 
Figure 4. Docked conformation of 14 (red), 30 (orange), 33 (purple) and 35 
(yellow) (A) into VEGFR-2 (PDB ID 2qu5, blue ribbon). As reference the co-
crystallized ligand is also displayed in black. The surface of ATP and co-
crystallized inhibitor binding site is also shown in light gray. Merged in the steric 
(B) and electrostatic (C) 3-D QSAR maps. 
 
 
 
A 
 
 
B C 
Figure 5. Docked conformation of 2f (magenta) (A) into VEGFR-2 (PDB ID 
2qu5, blue ribbon). The ATP binding site is also shown in light gray. Merged in 
the steric (B) and electrostatic (C) 3-D QSAR maps. 
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A B 
  
C D 
Figure 6. Details of the binding for compounds 2f, overlapped to 14 (A), 30 (B), 
33 (C) and 35 (D). 
 
 
 
 
Figure 7. Binding mode analyses suggest to introduce further substituent on the   
2f  piperidine ring. 2f is shown in magenta. The grey background represent the 
ATP binding site. 
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APPENDIX A 
Table A1. Predicted pIC50 for compounds 14, 30, 33 and 35. 
# Molecular Structure Exp. 
3-D QSAR Probes 
A C HD e 
14 
 
4.34 5.98 5.99 6.31 7.27 
30 
 
5.39 6.00 6.01 6.35 7.27 
33 
 
4.78 6.00 6.00 6.35 7.28 
35 
 
4.58 7.11 7.12 7.48 7.19 
 
 
Table A2. Designed Compounds. 
 
  
57 
 
Bibliography 
1. Fava, G. A., Affective disorders and endocrine disease. New insights from 
psychosomatic studies. Psychosomatics 1994, 35, 341-53. 
2. Folkman, J., Anti-angiogenesis: new concept for therapy of solid tumors. 
Annals of surgery 1972, 175, 409-16. 
3. Liotta, L. A.; Steeg, P. S.; Stetler-Stevenson, W. G., Cancer metastasis and 
angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64, 327-
36. 
4. Ferrara, N., VEGF and the quest for tumour angiogenesis factors. Nature 
reviews. Cancer 2002, 2, 795-803. 
5. Ferrara, N.; Kerbel, R. S., Angiogenesis as a therapeutic target. Nature 2005, 
438, 967-974. 
6. Ferrara, N.; Gerber, H. P.; LeCouter, J., The biology of VEGF and its 
receptors. Nature medicine 2003, 9, 669-76. 
7. Ferrara, N.; Hillan, K. J.; Gerber, H. P.; Novotny, W., Discovery and 
development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature 
reviews. Drug discovery 2004, 3, 391-400. 
8. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; 
Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; 
Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; 
Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A., BAY 
43-9006 exhibits broad spectrum oral antitumor activity and targets the 
RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor 
progression and angiogenesis. Cancer research 2004, 64, 7099-109. 
9. Motzer, R. J.; Michaelson, M. D.; Redman, B. G.; Hudes, G. R.; Wilding, 
G.; Figlin, R. A.; Ginsberg, M. S.; Kim, S. T.; Baum, C. M.; DePrimo, S. E.; Li, J. 
Z.; Bello, C. L.; Theuer, C. P.; George, D. J.; Rini, B. I., Activity of SU11248, a 
multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-
derived growth factor receptor, in patients with metastatic renal cell carcinoma. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 2006, 24, 16-24. 
10. Almog, N.; Ma, L.; Raychowdhury, R.; Schwager, C.; Erber, R.; Short, S.; 
Hlatky, L.; Vajkoczy, P.; Huber, P. E.; Folkman, J.; Abdollahi, A., Transcriptional 
switch of dormant tumors to fast-growing angiogenic phenotype. Cancer research 
2009, 69, 836-44. 
11. Gimbrone, M. A., Jr.; Leapman, S. B.; Cotran, R. S.; Folkman, J., Tumor 
dormancy in vivo by prevention of neovascularization. The Journal of 
experimental medicine 1972, 136, 261-76. 
58 
 
12. Baka, S.; Clamp, A. R.; Jayson, G. C., A review of the latest clinical 
compounds to inhibit VEGF in pathological angiogenesis. Expert opinion on 
therapeutic targets 2006, 10, 867-76. 
13. Sepp-Lorenzino, L.; Thomas, K. A., Antiangiogenic agents targeting 
vascular endothelial growth factor and its receptors in clinical development. Expert 
opinion on investigational drugs 2002, 11, 1447-65. 
14. Supuran, C. T.; Scozzafava, A., Protein tyrosine kinase inhibitors as 
anticancer agents. Expert Opinion on Therapeutic Patents 2004, 14, 35-53. 
15. Musmuca, I.; Caroli, A.; Mai, A.; Kaushik-Basu, N.; Arora, P.; Ragno, R., 
Combining 3-D quantitative structure-activity relationship with ligand based and 
structure based alignment procedures for in silico screening of new hepatitis C 
virus NS5B polymerase inhibitors. Journal of chemical information and modeling 
2010, 50, 662-76. 
16. Ragno, R. VEGFR-2 Inhibitors. Ligand-Based, Structure-Based and 3-D 
QSAR Studies as Tools to Design New Small Molecules. In XXIII Congresso 
Nazionale della Società Chimica Italiana, Sorrento, Italy, 2009; Sorrento, Italy, 
2009. 
17. Perspicace, E.; Jouan-Hureaux, V.; Ragno, R.; Ballante, F.; Sartini, S.; La 
Motta, C.; Da Settimo, F.; Chen, B.; Kirsch, G.; Schneider, S.; Faivre, B.; Hesse, 
S., Design, synthesis and biological evaluation of new classes of thieno[3,2-
d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial 
growth factor receptor-2 (VEGFR-2). European journal of medicinal chemistry 
2013, 63, 765-81. 
 
 
59 
 
Chapter VI 
Pharmacophore assessment through 3-D QSAR: Evaluation of the predictive 
ability on new derivatives by the application on a series of antitubercular 
agents 
Laura Friggeri, Flavio Ballante, Rino Ragno, Ira Musmuca, Daniela De Vita, 
Fabrizio Manetti, Mariangela Biava, Luigi Scipione, Roberto Di Santo, Roberta 
Costi, Marta Feroci, and Silvano Tortorella 
Journal of Chemical Information and Modeling 2013 53 (6), 1463-1474  
 
Preamble 
In this study, a series of 71 published anti-tubercular agents,
1-3
 was used as a 
training set to build, through the 3-D QSAutogrid/R procedure, 8 monoprobe 3-D 
QSAR PLS models, and a final multiprobe (MP) 3-D QSAR PLS model, able to 
quantitatively correlate the pharmacophoric features required for antitubercular 
(anti-TB) activity with molecular structures. All the 3-D QSARs were assessed by 
comparing their results with a previously published qualitative pharmacophoric 
model for anti-TB activity, with particular attention for the MP derivation. The 
obtained 3-D QSAR models were also tested for their predictive ability on a series 
of new synthetized R-4-amino-3-isoxazolidinone derivatives, confirming to be a 
promising tool for subsequent virtual screening (VS) applications. 
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Figure 1. Computational procedure. 
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Introduction 
Tuberculosis (TB) is a serious, as yet unsolved, public-health problem.
4
 There are 
several reasons that make difficult its eradication, such as long-term drug 
treatment, poor patient compliance and the development of drug resistant strains 
like: multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant 
tuberculosis (XDR-TB) and totally-drug resistant tuberculosis (TDR-TB).
5, 6
 
Therefore, the development of new anti-TB compounds is mandatory in a period in 
which the spread of HIV has determined, inevitably, a worldwide increase in TB. 
The study characterizing this chapter, allowed, without any available 
crystallographic data, to derive, through the 3-D QSAutogrid/R procedure
7
 several 
3-D QSAR monoprobe models, and a first three-dimensional pharmacophoric 
model (by the means of the MPGRS package)
7
 able to quantitatively inspect the 
areas and features fundamental for anti-TB activity. All the 3-D QSARs were 
compared to a previously qualitative pharmacophore model,
8, 9
 and tested for their 
predictive capabilities against an external test set composed of 13 newly 
synthetized R-4-amino-3-isoxazolidinone derivatives
10
 endowed with micromolar 
activity against M. tuberculosis (Figure 1 shows the whole procedure).  
 
Methodology 
Starting from a data set composed by 90 thiomorpholines and methylpiperazinyl 
compounds based on the Pyrrole ring as a scaffold,
1-3
 for which activity data was 
originally determined as MIC (µg/mL) and used to derive a previously reported 
qualitative pharmacophore model,
8, 9
 a final training set of 71 compounds 
(Appendix A Table A1), was selected by application of the inner relationship 
analysis. It was decided to apply the inner relationship investigation in order to 
improve the robustness and the predictive capability of the 3-D QSAR models: this 
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method, generally, allows to discard, from the training set, those molecules 
recognized as potentially detrimental for the PLS application. Since no 
crystallographic data was available for these compounds, the same alignment 
protocol, used to derive the previously developed qualitative pharmacophore 
model for anti-TB,
8, 9
 was adopted.
10
 By the application of the 3-D QSAutogrid/R 
procedure,
7
 8 monoprobe 3-D QSAR PLS models (Table 1) were built, and 
optimized through the CAPP procedure,
7
 then, by means of MPGRS package,
7
 a 
final multiprobe (MP) 3-D QSAR PLS model (Table 2) was derived. Cross-
validations (LOO and K5FCV) and Y-scrambling (YS) investigation, confirmed 
both their internal predictive capability and the absence of chance correlation 
(Tables 1 and 2). Either the best monoprobe (A, HD, and NA, Figure 2) and 
multiprobe models were then selected at the optimal principal component (PC)
7
 for 
further analyses. 
 
Table 1. 3-D QSAutogrid/R PLS models statistical results (CAPP process was 
applied). 
model P PC r
2
 q
2
LOO q
2
K5FCV r
2
YS q
2
YS V 
1 A 3 0.92 0.86 0.85 0.36 -0.33 3758 
2 C 3 0.92 0.86 0.85 0.37 -0.33 4492 
3 HD 3 0.91 0.85 0.84 0.39 -0.31 1217 
4 NA 3 0.91 0.86 0.85 0.31 -0.33 531 
5 N 3 0.91 0.85 0.85 0.32 -0.30 477 
6 OA 3 0.91 0.85 0.85 0.36 -0.33 658 
7 e 4 0.88 0.78 0.76 0.40 -0.48 468 
8 d 4 0.91 0.85 0.84 0.35 -0.44 4412 
P: Autogrid Probe, PC: optimal number of principal components/latent 
variables, r
2
: conventional square-correlation coefficient; q
2
LOO: cross-
validation correlation coefficient using the leave-one-out method; q
2
K5FCV: 
cross-validation correlation coefficient using the k-fold cross-validation with 5 
random groups and 100 iterations; r
2
YS: average square-correlation coefficient 
obtained after Y-scrambling process using 100 iterations; q
2
YS: average cross-
validation correlation coefficient using the leave-one-out method obtained 
after Y-scrambling process using 100 iterations; V: number of active variables. 
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Table 2. MPGRS. Multi Probe model statistical results. 
  MPGRS 3-D QSAR   
PCFL:SL 
1:3 
r
2
 q
2
LOO q
2
K5FCV SDEPLOO SDEPK5FCV r
2
YS q
2
YS 
0.88 0.80 0.80 0.32 0.32 0.31 -0.31 
PCFL:SL: optimal number of principal first level (FL) and second level (SL) 
components for the MPGRS model; r
2
: conventional square-correlation coefficient; 
q
2
LOO: cross-validation correlation coefficient using the leave-one-out method; 
q
2
K5FCV: cross-validation correlation coefficient using the k-fold cross-validation 
with 5 random groups and 100 iterations. 
 
Single Probe 3-D QSAR models 
Analyses of PLS-coefficients plots allowed to define, in complete agreement with 
the original qualitative pharmacophoric model,
8, 9
 the needed chemical 
characteristics for anti-TB activity of pyrrole compounds. As for example, PLS-
coefficients plots (Figures 3A, 3B, 3C) defined four areas: over N1, C2, C3, and 
C5 substituents of the pyrrole ring, similarly to those obtained
9
 from the original 
model (Figure 3D) which defined 4 pharmacophoric features: a hydrogen bond 
acceptor feature (HBA), two aromatic ring features (RA1, RA2), and an 
hydrophobic feature (HY). All the selected monoprobe models suggested the 
positive effect (red colored positive PLS coefficients, Figure 3) of bulky groups as 
substituent at N1, C2 and C5, respectively overlapping the HY, RA1 and RA2 
features; on the contrary at the C3 position (HBA feature) steric groups are less 
tolerated (blue colored, negative PLS coefficients, Figure 3A and 3C) whereas 
attractive interactions could increase the biological activity (blue colored, negative 
PLS coefficients, Figure 3B). Since activity contribution plots have the capability 
to show the recalculated 3-D activity profile for each molecule, it was possible to 
highlight, more specifically, how the quantitative models predicted the effects of 
each training set molecule three dimensionally.  
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Analysis of these maps confirmed, generally, the information addressed by the 
PLS-coefficients plots and allowed to highlight some dependencies between the 
anti-tubercular activity and the chemical structures. In particular, considering the 
HBA feature, the HD model plot (Figure 4) clearly showed how the sulfur atom in 
a thiomorpholine group (characterizing the most active compound 60, Figure 4A) 
 
A 
 
B 
 
C 
 
D 
Figure 2. Fitting (r
2
) and Cross-Validation (q
2
 K-5-Fold) plots. A: from the A 
probe model at PC3; B:from HD probe model at PC3; C:from the NA probe model 
at PC3; D: from the multi probe(MP) model at PC1:3. 
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increases the biological activity (satisfying the HBA feature), contrary to a 
situation in which, as for the case of methylpiperazinyl derivatives, repulsive 
interactions are mainly present in the same area (i.e. the least active molecule 21, 
Figure 4B). Moreover, different useful informations were obtained from the 
simultaneous analysis of PLS-loadings and score plots’ clusters, considering the A 
probe model at the first three principal components (Figure 5), allowing to 
understand how different molecular conformations and substituents’ orientations 
could affect the biological response. Starting from the first principal component 
(PC1) was possible to determine that the region between RA2 and HBA features 
should be preferably occupied than those between RA1 and HBA; PC2 and PC3 
highlighted, respectively, how substituents at C3 capable to fill the areas between 
RA2 and HBA and over HBA features determine a detrimental effect on the 
biological activity.  
Multi-Probe Guided Region-Variable Selection 
The MPGRS package
7
 allowed to derive the first quantitative pharmacophoric 
model able to correlate the structural features of pyrrole derivatives with their 
biological data. The optimal MP 3-D QSAR model (Table 2) was characterized by 
standard coefficients similar to those of the monoprobe models (Table 1), but the 
interpretation was greatly enhanced since all the different monoprobe suggestions 
were condensed together. By analyzing the different plots, similar conclusion to 
those obtained from the different mono-probe models were obtained, moreover 
new information was found. As reported extensively,
10
 by means of PLS-
coefficients, PLS-loadings plots and score results (Figures 6 and 7) was possible to 
increase the resolution of the HBA region revealing, in addition to the electrostatic 
feature, that a limited steric repulsion is tolerated (Figures 6A and 6B, Appendix A 
Table A3). Moreover, figure 6B shows how the thiomorpholinometil moiety of 
compound 60 (the most active compound) satisfies both of these features, leading 
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to higher anti-tubercular activity, contrary to compound 21 (the least active 
compound). 
External test set Prediction analysis 
All the 3-D QSARs were externally validated using a set composed of 13 newly 
synthesized R-4-amino-3-isoxazolidinone derivatives (Table A2), previously tested 
against the M. tuberculosis (Appendix A Table A4). All the 3-D QSARs were able 
to predict these compounds with low SDEP values, confirming the robustness and 
predictability of the models. 
 
Table 3. Test Set predictions. 
P PC SDEPEXT 
A 3 0.88 
C 3 0.88 
HD 3 0.81 
NA 3 0.82 
N 3 0.83 
OA 3 0.84 
e 4 0.90 
d 4 1.51 
SDEP values considering the optimal PCs; P: AutoGrid Probe; PC: 
optimal number of principal components/latent variables; SDEPEXT: 
standard deviation error of prediction (or root mean squared error of 
prediction, RMSEP) for the external test set. 
 
Table 4. MPGRS. Multi Probe model Test Set predictions. 
P PCFL:SL SDEPEXT 
AutoGrid MP 1:3 0.89 
SDEP values considering the optimal first level and second level PCs. P: AutoGrid 
Multi-Probe; PCFL:SL: optimal first level and second level PC; SDEPEXT: standard 
deviation error of prediction (or root mean squared error of prediction, RMSEP) 
for the external test set. 
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Perspectives 
The obtained quantitative models were then integrated, together with QSAR 
applications, in an optimized Virtual Screening (VS) protocol, initially validated 
using the CHEMBL database and finally applied to NCI Diversity Set. A total of 
120 molecules have been identified as potential anti-tuberculosis agents for which 
it will be determined the anti-mycobacterial activity 
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A 
 
B 
 
C 
 
D 
Figure 3. The most active (60 in blue) and the least active (21 in magenta) 
compounds are shown. A: PLS-coefficients contour maps derived from A probe 
analysis (contour levels: 80%; positive: red, negative: blue); B: PLS-coefficients 
contour maps derived from HD probe analysis (contour levels: 85%; positive: red, 
negative: blue); C: PLS-coefficients contour maps derived from NA probe analysis 
(contour levels: 75%; positive: red, negative: blue). D: pharmacophoric features 
derived from the original pharmacophoric model:
9
 HY (hydrophobic feature), RA 
(aromatic feature), HBA (hydrogen bond acceptor feature). 
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                                                    A 
 
B 
Figure 4. Probe HD. A: PLS-coefficients (mesh: 85%, positive: red, negative: 
blue) with activity contribution (solid: 90%, positive: green, negative: yellow) for 
compound 60 (blue); B: PLS-coefficients (mesh: 85%, positive: red, negative: 
blue) with activity contribution (solid: 90%, positive: green, negative: yellow) for 
compound 21(magenta).Activity contributions in pictures on the left side are 
shown in color gradient: for both green and yellow polygons, the darker areas (the 
most important) are characterized by the highest numerical coefficients, the lighter 
areas (the less important) are characterized by the lowest numerical coefficients. 
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 PC1 PC2 PC3 
A 
   
B 
 
  
Figure 5. Probe A. PLS-loadings contour maps from the A probe analysis at PC1, 
PC2 and PC3 (contour levels: 60%; positive: orange, negative: cyan). The ten most 
important molecules for each cluster are plotted and color coded according to the 
cluster membership (molecules in the negative field cluster: dark grey, molecules 
in the positive field cluster: light grey). A:side view; B: top view. 
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A 
 
B 
 
C 
 
 
D 
Figure 6. MPGRS. A: key points: the points are color coded according to that 
reported in Table A3; B: key points with PLS-coefficients contour maps (contour 
levels: positive 85%, red; negative 95%, blue); C:top view, key points with PLS-
coefficients solid contour maps (contour levels: positive 85%, red; negative 95%, 
blue). The most active (60 in blue) and the least active (21 in magenta) compounds 
are shown. D: pharmacophoric features derived from the original pharmacophoric 
model:
9
 HY (hydrophobic feature); RA (aromatic feature), HBA (hydrogen bond 
acceptor feature). 
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A 
 
B 
 
B1 
 
B2 
Figure 7. MPGRS. PLS-loadings contour maps at PC1:3 (contour levels: 75%; 
positive: orange, negative: cyan) with PLS-coefficients (mesh levels: positive 85%, 
red; negative 95%, blue) and key points (see Table S5 for color coding). The ten most 
important molecules for each cluster are plotted and color coded (compounds in the 
positive loading field in light gray; compounds in the negative loading field in dark 
grey). A:side view; B: frontal view; B1: frontal view of only positive clustered 
molecules; B2: frontal view of only negative clustered molecules. HY (hydrophobic 
feature), RA (aromatic feature), HBA (hydrogen bond acceptor feature). 
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APPENDIX A1 
Table A1. Structure and antimycobacterial activity against M. tuberculosis 103471 
of the pyrrole derivatives used as training set for the generation of the 3-D QSAR 
models. 
 
compd
a
 R
b 
R1 R2 R3 pMIC
c 
1 B 2-F-Ph CH3 2-F-Ph 4.68 
2 A 2-Cl-Ph CH3 2-F-Ph 5 
3 B 2-Cl-Ph CH3 2-F-Ph 4.09 
4 A 2-F-Ph CH3 2-Cl-Ph 5 
5 B 2-F-Ph CH3 2-Cl-Ph 4.4 
6 A 2-Cl-Ph CH3 2-Cl-Ph 5.02 
7 B 2-Cl-Ph CH3 2-Cl-Ph 4.41 
8 A 2-F-Ph CH3 -naphthyl 4.11 
9 B 2-F-Ph CH3 -naphthyl 4.11 
10 A 2-Cl-Ph CH3 -naphthyl 4.13 
11 B 2-Cl-Ph CH3 -naphthyl 4.13 
12 A -naphthyl CH3 2-Cl-Ph 4.13 
13 B 4-F-Ph CH3 Ph 4.36 
14 B Ph CH3 4-F-Ph 4.36 
15 A 4-Cl-Ph CH3 4-F-Ph 5.30 
16 B 4-F-Ph CH3 4-F-Ph 4.47 
17 A 4-F-Ph CH3 4-F-Ph 5.58 
18 B 4-F-Ph CH3 4-Cl-Ph 5.30 
19 A 4-F-Ph CH3 4-Cl-Ph 5.60 
20 A 2-F-Ph CH3 Ph 4.66 
21 B 2-F-Ph CH3 Ph 4.06 
22 A Ph CH3 2-F-Ph 4.96 
23 B Ph CH3 2-F-Ph 4.36 
24 A 2-Cl-Ph CH3 Ph 4.38 
25 B 2-Cl-Ph CH3 Ph 4.07 
26 B Ph CH3 2-Cl-Ph 4.07 
27 A -naphthyl CH3 Ph 4.1 
28 B -naphthyl CH3 Ph 4.09 
29 A Ph CH3 -naphthyl 4.10 
30 B Ph CH3 -naphthyl 4.09 
31 B Ph CH3 Ph 4.33 
32 A 4-F-Ph CH3 2-Cl-Ph 5.00 
33 B 4-F-Ph CH3 2-Cl-Ph 4.70 
34 B 4-F-Ph CH3 2-F-Ph 4.08 
35 A 4-F-Ph CH3 4-CH3-Ph 5.98 
36 B 4-F-Ph CH3 3-CH3-Ph 4.37 
37 A 4-F-Ph CH3 2-CH3-Ph 4.98 
38 B 4-F-Ph CH3 2-CH3-Ph 4.07 
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39 A 4-F-Ph CH3 2,4-Cl2-Ph 5.34 
40 B 4-F-Ph CH3 2,4-F2-Ph 5.00 
41 A 2-Cl-Ph CH3 4-F-Ph 5.30 
42 B 2-Cl-Ph CH3 4-F-Ph 5.00 
43 B 2-F-Ph CH3 4-F-Ph 4.68 
44 A 4-CH3-Ph CH3 4-F-Ph 5.58 
45 A 3-CH3-Ph CH3 4-F-Ph 4.98 
46 B 3-CH3-Ph CH3 4-F-Ph 4.40 
47 A 2-CH3-Ph CH3 4-F-Ph 4.68 
48 B 2-CH3-Ph CH3 4-F-Ph 4.10 
49 A 2,4-Cl2-Ph CH3 4-F-Ph 5.64 
50 B 2,4-Cl2-Ph CH3 4-F-Ph 5.03 
51 A 2,4-F2-Ph CH3 4-F-Ph 5.30 
52 B 2,4-F2-Ph CH3 4-F-Ph 4.40 
53 A 4-F-Ph CH3 4-C2H5-Ph 5.60 
54 A 4-F-Ph CH3 4-i-propyl-Ph 6.21 
55 A 4-C2H5-Ph CH3 4-F-Ph 5.30 
56 A 4-C3H7-Ph CH3 4-F-Ph 5.61 
57 A 4-Cl-Ph CH3 4-CH3-Ph 5.90 
58 A 4-Cl-Ph CH3 4-C2H5-Ph 6.22 
59 A 4-Cl-Ph CH3 4-C3H7-Ph 6.23 
60 A 4-Cl-Ph CH3 4-i-propyl-Ph 6.53 
61 A 4-CH3-Ph CH3 4-Cl-Ph 5.90 
62 A 4-C2H5-Ph CH3 4-Cl-Ph 5.91 
63 A 4-C3H7-Ph CH3 4-Cl-Ph 6.23 
64 A 4-i-propyl-Ph CH3 4-Cl-Ph 6.23 
65 B 4-Cl-Ph C2H5 4-Cl-Ph 5.33 
66 A 4-F-Ph C2H5 4-CH3-Ph 6.20 
67 A Ph C2H5 Ph 5.26 
68 A Ph C2H5 4-F-Ph 5.58 
69 A 4-F-Ph C2H5 Ph 5.28 
70 A 2-F-Ph C2H5 4-F-Ph 5.30 
71 A 2-F-Ph C2H5 2-F-Ph 5.00 
c.
Compound enumeration was assigned on the basis of the original increasing 
numbering from the oldest to the most recent reference. Table S1shows the 
connections between the new and original enumerations. 
a
A = thiomorpholin-4-yl and B = 4-methylpiperazin-1-yl 
b
pMIC = -Log [MIC(µM) x 10
-6
] 
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Table A2. R-4-amino-3-isoxazolidinone derivatives: monocarbamates (1a-e), 
dicarbamates (2a-f) and amides (3h,i). 
 
Monocarbamates 1a-e 
 
Dicarbamates 2a-f 
# R1 R2 # R1 R2 
1a 
 
H 2a 
  
1b 
 
H 2b 
  
1c 
 
H 2c 
  
1d 
 
H 2d 
  
1e 
 
H 
2e 
  
2f 
  
 
 
3h 3i 
Amides 3h, 3i 
 
Table A3. List of the AutoGrid probes employed for MIF calculation and MPGRS 
subregion color coding. 
Probe Description MPGRS Colour 
A Aromatic Carbon Gray 
C Aliphatic (sp
3
) Carbon Dark Gray 
HD Hydrogen bonded to heteroatom Green 
NA Hydrogen-bond-accepting amine nitrogen Cyan 
N Amide nitrogen Blue 
OA Hydrogen-bond-accepting oxygen Red 
e Electrostatic Orange 
d Desolvation Yellow 
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Table A4. MIC data for D-4-amino-3-isoxazolidinone derivatives 
compd MIC(μg/mL)a pMICb 
1a 32 3.84 
1b 32 3.87 
1c 32 3.90 
1d 3.1 4.89 
1e 32 3.97 
2a 32 4.03 
2b 32 4.06 
2c 32 4.10 
2d 3.1 5.09 
2e 32 4.11 
2f 32 4.02 
3h 64 3.78 
3i 32 4.13 
a
M. tuberculosis H37Rv (ATCC 27294) was used; MIC values represent the 
minimal concentrations of compounds completely inhibiting visible growth of 
mycobacteria. 
b
pMIC = -Log [MIC(µM) x 10
-6
] 
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Chapter VII 
Hsp90 Inhibitors (I). Definition of 3-D QSAutogrid/R Models as a Tool for 
Virtual Screening 
Flavio Ballante, Antonia Caroli, Richard B. Wickersham III And Rino Ragno  
Journal of Chemical Information and Modeling, (2013, submitted) 
 
Preamble 
Acknowledged to play a key role in the growth and survival of cancer cells, the 
multi-chaperone heat shock protein (Hsp) 90 represents a promising target in 
cancer therapy. This chapter describes a complete computational procedure, for 
building several structure based (SB) 3-D QSAR models used to derive a final 
multi-probe (MP) 3-D QSAR pharmacophoric model, able to recognize the most 
significant chemical features for HSP90 inhibition. All the 3-D QSARs, either 
mono- and multi-probe, built by means of the 3-DQSAutogrid/R protocol (Chapter 
II), were externally validated for robustness and predictiveness, and recognized 
suitable to be used as a predictive tool in a subsequent virtual screening (VS) 
protocol whose application and results are reported in Chapter VIII. 
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Introduction 
Molecular chaperones are cellular machinery that assist the protein folding under 
physiological (playing a key role in protein maturation and stabilization) and stress 
conditions (preventing the formation of a misfolded or aggregated structure).
1
 
Among chaperones, the 90 kDa heat shock protein (Hsp90) gained much attention 
in recent years being one of the most extensively studied.
2, 3
 Structurally, Hsp90 is 
a dimeric protein composed of three functional domains: 1) a highly conserved N-
terminal ATP-binding domain, 2) a middle domain endowed with high affinity for 
client proteins and 3) a highly conserved C-terminal domain involved in the 
homodimerization of the protein.
4
  
Hsp90 is present in cells in two isoforms, α (inducible, major form) and β 
(constitutive, minor form) found predominantly in the cytosol, and two paralogues, 
ER-resident Grp94 and mitochondrial tumor necrosis factor receptor-associated 
protein 1 (Trap1). Under basal, non-stressed conditions Hsp90 comprises 
approximately 1% of the cellular protein population whereas its expression 
increases significantly after exogenous injury:
5
 indeed, during some cellular stress 
conditions, such as heat, low pH, nutrient unavailability, hypoxia and malignancy, 
Hsp90 is overexpressed, promoting the maintenance of structural and functional 
integrity of client proteins involved in cell survival, proliferation and apoptosis. As 
reported,6 pharmacological inhibition of Hsp90 destabilizes proteins, leading to 
their degradation through the proteasome; moreover, many oncogenic proteins (i.e. 
p53 mutants, Raf1, Akt, Bcr-Abl, Her2, EGFR) which are essential for tumor 
growth are chaperoned by the Hsp907 confirming its involvement in the tumor 
progression. Since the inhibition of Hsp90 ATPase activity leads to the degradation 
of client proteins, resulting in cell growth inhibition and apoptosis, Hsp90 emerged 
as a promising target for cancer therapy.8 Natural products such as geldanamycin9 
and radicicol10 were among the first Hsp90 inhibitors discovered (Figure 1), 
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followed by derivatives with better pharmacological properties (17-AAG11 and 17-
DMAG,12 Figure 1). Considering that blocking the ATPase activity is an effective 
approach, de novo drug design was accomplished and small molecules able to bind 
the N-terminal Hsp90 binding site were identified. Purine-scaffold inhibitors,13 
dihydroxyphenylpyrazoles, 14 isoxazole derivatives (NVPAUY922), 15 and 
carbazol-4-one benzamide derivatives (SNX-5422)16 were promising candidates for 
cancer therapy and advanced to clinical studies (Figure 1).  
 
 
R Cpd 
-OMe GELDANAMYCIN 
-NHCH2CH2NMe2 17-DMAG 
-NHCH2CH=CH2 17-AAG 
 
 
RADICICOL 
  
 
NVP-AUY922 
 
SNX-5422 
Figure 1. Hsp90 inhibitors: the ansamycin compound geldanamycin and its 
derivatives radicicol, isoxazole (NVP-AUY922) and carbazol-4-one benzamide 
(SNX-5422); all of these are in clinical trials. 
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Despite the huge amount of available data (until now 310 X-ray structures are 
reported in Protein Data Bank,17 199 of which were from Homo Sapiens), only a 
limited number of 3-D QSAR applications were reported.4, 20-27  
In the present work, the 3-D QSAutogrid/R procedure18 (Chapter II) was applied to 
a dataset composed of 24 Hsp90/inhibitor co-crystals (Appendix A Table A1) to 
define three-dimensional quantitative structure-activity relationship (3-D QSAR) 
models. These were used to derive pharmacophoric quantitative models (as 
described in the anti-TB application Chapter VI)19 by the application of Multi 
Probe Guided Region Selection (MPGRS package),18 to correlate structural Hsp90 
inhibitors features with their biological data. All 3-D QSAR models were 
externally validated for robustness and predictiveness as a tool in the subsequent 
virtual screening (VS) protocol (Chapter VIII). Figure 2 shows the overall 
procedure. 
 
Figure 2. Computational procedure. 
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Computational methods 
At the beginning of this study, all the co-crystallized ligand-protein complexes, 
available from the Protein Data Bank (PDB),17 were retrieved. From these, 24 were 
selected (Appendix A Table A1) as molecular dataset and submitted to a 
minimization process. Then, the ligands were extracted from the complexes and 
split into a training set and a test set composed of 15 and 9 compounds, 
respectively. By means of 3-D QSAutogrid/R procedure,18 a total of nine 3-D 
QSAR models were built: 8 monoprobe and a final multiprobe (MP). All the 
training set inhibitors were used in a ligand (LB) and structure-base (SB) protocols 
to validate the alignment procedure that was applied on new candidates (with 
unknown binding mode) during the subsequent virtual screening (VS) application, 
in which the 3-D QSARs were used as an external scoring function to predict their 
activity, as reported in Chapter VIII. 
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Data Set Selection 
Initially, 39 co-crystallized ligand-protein complexes were available from the 
PDB,17 for which in vitro activity was determined mostly through two conventional 
biological assays: the measure of the ATPase activity (ATPase assay) and the 
measure of competitive inhibition using a fluorescent probe (Fluorescence 
Polarization). From these, 24 were tested with the same approach (ATPase assay, 
IC50 values), resulting eligible to be used in a 3-D QSAR application. The data set 
compounds (Appendix A Table A1) are structurally related to purine,13 pyrazole,17, 
38 2-aminopyrimidine,7 triazine7 and N-aryl-benzimidazolone20 scaffolds. 
 
N-terminal Hsp90 Binding Site-Inhibitor Complex Structure Preparation 
The 24 selected complexes were submitted to a previously reported molecular 
modeling protocol,21 then the minimized conformations of ligands, as extracted 
from the minimized complexes, were split in training and test sets (see Training 
Set and Test Set selection paragraph) to build and validate the structure-based 
statistical models (3-D QSAR), respectively. 
 
Training Set and Test set selection 
The data set was partitioned to maintain a similar range of activities between the 
training and test sets: in particular, the former was composed of 15 compounds 
(Appendix A, Table A2) with affinity values spanning about 3 orders of 
magnitude, from pIC50 values of 3.70 to 6.26, and the latter was comprised of 9 
compounds (Appendix A, Table A3) with affinity values ranging from 3.70 to 
6.28.  
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Results and Discussion 
By means of the 3-D QSAutogrid/R procedure,18 eight mono-probe 3-D QSAR 
PLS models were generated and optimized via the CAPP18 procedure (Table 1). 
 
Then, by the application of the MPGRS procedure,18 a final multi probe (MP) 
model was derived to define the pharmacophoric features required for Hsp90 
inhibitor activity and quantitatively correlate them with molecular structures (See 
below in the Multi-Probe Guided Region-Variable Selection paragraph). The 
obtained statistical results confirmed the predictive capabilities and robustness of 
the mono-probe models (Table 2).  
 
Table 2. Autogrid/R PLS models statistical results (CAPP process was applied). 
model  P PC r
2
 q
2
LOO q
2
K5FCV r
2
YS q
2
YS 
1  A 2 0.93 0.61 0.59 0.69 -0.46 
2  C 2 0.93 0.61 0.58 0.69 -0.50 
3  HD 2 0.85 0.55 0.54 0.44 -0.52 
4  NA 2 0.93 0.61 0.59 0.71 -0.42 
5  N 2 0.93 0.62 0.58 0.68 -0.52 
6  OA 2 0.93 0.61 0.59 0.69 -0.47 
7  e 2 0.93 0.63 0.60 0.73 -0.50 
8  d 1 0.72 0.61 0.60 0.12 -0.22 
P:Autogrid Probe, PC: optimal number of principal components/latent variables, r
2
: conventional 
square-correlation coefficient; q
2
LOO: cross-validation correlation coefficient using the leave-one-
out method; q
2
K5FCV: cross-validation correlation coefficient using the k-fold cross-validation 
with 5 random groups and 100 iterations; r
2
YS: average square correlation coefficient obtained 
after Y-scrambling process using 100 iterations; q
2
YS: average cross-validation correlation 
coefficient using the leave-one-out method obtained after Y-scrambling process using 100 
iterations. 
Table 1. CAPP settings adopted for the 3-D QSAR models. 
Min Value Parameter Max Value Step 
0 PCO 10 1 
0 Zeroing 0.1 0.01 
0 MSDCO 1 0.025 
PCO: Positive Cut Off, Zeroing: zeroing of very low data points ,MSDCO: Minimum SD Cut Off. 
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Three of them, obtained with A, N and OA probes (Figure 3), were selected, for 
further investigations. 
 
Score and PLS-loadings plots were useful to detect the putative most important 
residues for each cluster of molecules detected by the score plots. Since similar 
results were obtained from all the three analyzed monoprobe models, only those 
 
A 
 
B 
 
C 
Figure 3. Fitting (r
2
, cyan points) and Cross-Validation (q
2
 K-5-Fold, orange 
points) plots. A: from the A probe model at PC2; B:from N probe model at PC2; 
C:from the OA probe model at PC2. 
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obtained from the aromatic (A) are reported. Starting from PC1 (Figure 4A) a clear 
discrimination between low (pIC50 ≤ 5) and high active compounds (pIC50> 5) was 
observed: indeed molecules characterized by the lowest activities such as all the 
purine based inhibitors13 (1UY8, 1UYC, 1UYD, 1UYE, 1UYG, 1UYH, 1UYK, red 
bars in Figures 4A) and 3B257 (light green bar) are clustered in the negative field, 
whereas most of the more active compounds like: pyrazole
14, 22
 and N-Aryl-
benzimidazolone
20
 derivatives (2BT0, 2CCS, 2CCU, 3OWB, 3OWD, olive drab 
and blue bars respectively) are grouped in the positive PC1 score field. 2-
aminopyrimidine and triazine derivatives7 (3B26 and 3B28, light green and dark 
green bars respectively) were characterized by low absolute PC1 score values. 
Considering the association between scores and PLS-loadings, was possible by 
superimposing the latters (LB extracted data) with the residues active site (SB info) 
to detect the putative most interacting residues for each cluster (Figures 5 and 6) on 
the basis of the first principal component (PC1) information. As shown in Figure 
5A two “posing” areas were revealed as the main discriminating aspect between 
these two molecular series. By PLS-loadings analysis (Figure 6A) a series 
composed of GLY97, ILE96, ASP54, ALA55, LEU48, LYS58 and VAL186 was 
recognized to interact mainly with the positive clustered molecules (2BT0, 2CCS, 
2CCU, 3OWB, 3OWD), whereas a second series composed of LEU107, TYR139 
and PHE138 was recognized to interact mainly with the negatives (1UY8, 1UYC, 
1UYD, 1UYE, 1UYG, 1UYH, 1UYK and 3B25). This fact suggested the 
importance in establishing interactions with the first series residues (LB/SB 
convergence point 1, Table 3). From PC2 (Figure 4B, 5B), this kind of analysis, 
suggested that a steric group overlapping the corresponding benzyl para-methoxy 
group of 1UYD (Figure 6B) is detrimental for the activity, indeed from the 
superimposed crystals, the presence of a conformationally conserved TYR139 
side-chain in this area suggests a consequent steric limitation for bulkier ligands 
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(LB/SB convergence point 2, Table 3). Analyses of PLS-coefficients (ligand-based 
information) overlapped to the binding pockets (structure-based information) 
allowed a quali/quantitative definition of the different ligand/receptor interactions, 
extending the evidences provided by the PLS-loadings/PLS-scores interpretation. 
A good agreement was observed between the quantitative derivation (PLS-
coefficients) and the experimental information (binding pocket residues, Figure 7): 
i.e. considering the aromatic atom probe A at PC2, the biggest positive coefficients 
area was mainly located in the sub-pocket delimited by LYS58, ILE96 and, 
GLY97 residues (Figure 7), suggesting that bioactivity improvement could be 
obtained by filling this hydrophobic area (LB/SB convergence point 3, Table 3) in 
agreement with previous reports.
23, 24
 
Negative PLS-coefficients were mainly placed in a space surrounded by LEU107, 
TYR139 and PHE138, confirming, as anticipated above (see PLS-loadings 
interpretation), a steric hindrance limitation exerted by TYR139 and PHE138 side 
chains (LB/SB convergence point 4, Table 3, Figure 7). As a consequence 
molecules such as the ligand in 1UYD, which overlaps this area, are less active. 
A further smaller negative PLS-coefficients area runs among ALA55, SER52 and 
ASP93 (small blue area in Figure 7) and, considering also both results from OA 
PLS-coefficients (also negative), these suggest the presence of both steric and 
electrostatic features in this zone. In fact, these features represent a further LB/SB 
convergence point (LB/SB convergence point 5, Table 3) by the presence of 
electrostatic interactions with the three above listed residues (i.e H bonds), in 
agreement with previous reports. 25 
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A 
 
B 
Figure 4. Aromatic atom (A) probe scores plots. Compounds are color-coded 
according to their scaffold: purine based inhibitors (entries: 1,2,3,4,5,6,7): red bars, 
2-aminopyrimidine inhibitors (entries: 17, 18): light green bars, pyrazole inhibitors 
(entries: 13, 14, 16, 21): olive drab bars, N-Aryl-benzimidazolone inhibitors (entry: 
22): blue bars, triazine inhibitors (entry: 20): dark green.  
 
 
 
 
 
 
 
 
 
89 
 
 
 
A1 
 
A2 
 
B1 
 
B2 
Figure 5. Probe A. A: PLS-loadings contour maps from the A probe analysis at 
PC1 (contour levels: solid 30%, mesh 60%; positive: orange, negative: cyan). All 
the molecules for each cluster are plotted and color coded according to the cluster 
membership (molecules in the negative field cluster: black, molecules in the 
positive field cluster: light grey, molecules in the center field cluster: dark grey). 
A1: front view; A2: top view. B: PLS-loadings contour maps from the A probe 
analysis at PC2 ( contour levels: solid 30%, mesh 60%; positive: orange, negative: 
cyan ). All the molecules for each cluster are plotted and color coded according to 
the cluster membership (molecules in the negative field cluster: black, molecules in 
the positive field cluster: light grey, molecules in the center field cluster: dark 
grey). B1: front view; B2: top view. Double level percentage is shown to with the 
purpose to point out together the most influencing loadings. 
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A 
 
B 
Figure 6. Probe A. A: PLS-loadings contour maps from the A probe analysis at 
PC1 (contour levels: mesh 30%; positive: orange, negative: cyan). In magenta 
3OWD (positive cluster), in green 1UYD (negative cluster), in orange 3B28 
(neutral cluster); B: PLS-loadings contour maps from the A probe analysis at PC2 
(contour levels: mesh 50%; positive: orange, negative: cyan).In orange 3B28 
(positive cluster), in green 1UYD (negative cluster), in purple 3OWB (neutral 
cluster). 
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Table 3. LB/SB convergence points. 
N. 
Reference 
Probe 
Reference 
PC 
Information LB/SB convergence 
1 
A, N, OA/ 
MP 
1/1:1 
PLS Scores 
PLS Loadings 
X-ray 
Interactions with GLY97, ILE96, 
ASP54, ALA55, LEU48, LYS58, 
VAL 186 are desirable 
2 
A, N, OA/ 
MP 
2/1:2 
PLS Scores 
PLS Loadings 
X-ray 
Steric hindrance limitation near 
TYR139, TRP162 
3 
A, N, OA/ 
MP 
2/1:2 
PLS 
Coefficients 
X-ray 
The hydrophobic sub-pockets 
composed of LYS58, ILE96 and 
GLY97, and VAL186 and LEU48, 
respectively, should be fulfilled 
4 A, N, OA 2 
PLS 
Coefficients 
X-ray 
Steric hindrance limitation exerted 
by TYR139 and PHE138 
5 
A, N, OA/ 
MP 
2/1:2 
PLS 
Coefficients 
X-ray 
Electrostatic interactions with 
ALA55, SER52, ASP93, THR184 
and ASN51 should be preferable 
6 MP 1:2 
PLS 
Coefficients 
X-ray 
Electrostatic interactions with the 
para-hydroxylic group of TYR139 
could be advantageous; weak 
attractive interactions with  the 
indole nitrogen of TRP162 could be 
established 
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Figure 7. PLS-coefficients contour maps considering 2 PCs. Only the highest 
active (3OWD in magenta) and the lowest active (1UYD in green) compounds are 
shown. AutoGrid/R PLS coefficients contour maps derived from A probe analysis 
(Contour levels: 65%, positive red, negative blue. 
 
Application of Multi-Probe Guided Region-Variable Selection 
A multi-probe (MP) 3-D QSAR model was derived by the application of the Multi 
Probe Guided Region Selection (MPGRS package).
18
 As reported, the MP 3-D 
QSAR model is obtained at the optimal second level PC of the selected first level 
PC subregions; in this case PCFL:SL=PC1:2, and its associated statistical 
coefficients were slightly improved with respect to those of the mono-probe 
models (Table 4, Figure 8). 
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Table 4. Statistical Results Obtained from MPGRS Analysis 
  MPGRS 3-D QSAR   
PCFL:SL 
1:2 
r
2
 q
2
LOO q
2
K5FCV SDEPLOO SDEPK5FCV r
2
YS q
2
YS 
0.94 0.69 0.68 0.43 0.44 0.67 -0.50 
PCFL:SL: optimal number of principal first level (FL) and second level (SL) 
components for the MPGRS model; r
2
: conventional square-correlation coefficient; 
q
2
LOO: cross-validation correlation coefficient using the leave-one-out method; 
q
2
K5FCV: cross-validation correlation coefficient using the k-fold cross-validation 
with 5 random groups and 100 iterations 
 
 
 
Analyses of multi probes scores and loadings led to similar conclusions as the 
mono-probe models (LB/SB convergence points 1 and 2, Table 3), however, a 
higher level interpretation allowed identifying both the areas of major interest and 
the more profitable associated features (Figure 8).  
 
 
 
Figure 8. MPGRS. Fitting (r
2
, cyan points) and Cross-Validation (q
2
 K-5-Fold, 
orange points) plot: from the multi probe(MP) model at PC1:2. 
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A 
Figure 8. MPGRS. A: key points with PLS-coefficients contour maps (contour levels 
75%: positive: red; negative: blue). 3OWD in magenta and 1UYD in green. The 
points are color coded according to that reported in the methodology reference. 
 
 
Of particular interest are areas simultaneously characterized by negative MP PLS 
coefficients associated to atom probes able to derive negative fields such as OA, 
NA and HD. In particular, two distinct areas of negative MP PLS coefficients 
derived from OA probe are among THR184, ASP93, SER52 and ASN51 (Figure 
9A) and TRP162, TYR139 and LEU107 (Figure 9B), suggesting that the 
establishment of attractive interactions (i.e. H-bond) should be advantageous in the 
proximity of the first residues’ series as for the para-hydroxylic group of TYR139 
(LB/SB convergence points 5 and 6, Table 3). Furthermore, between TYR139 and 
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TRP162, a negative PLS-coefficient area (Figure 9B), characterized by NA and C 
probes, was observed, which suggests, besides the steric limitation, that some weak 
attractive interaction with the indole nitrogen of TRP162 could be established 
(LB/SB convergence points 2 and 6, Table 3). Finally, two positive coefficient 
polyhedra, characterized both by steric/hydrophobic and electrostatic probes (A, C, 
OA, N and NA), were recognized in the proximity of LYS58 and ILE96, and 
VAL186 and LEU48 (Figures 9C and 9D, respectively) confirming the importance 
of placing steric groups in these areas (LB/SB convergence point 3, Table 3). 
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A 
 
B 
 
C 
 
D 
Figure 9. MPGRS. A-D: PLS-coefficients contour maps (contour levels 75%: 
positive: red; negative: blue), each area is highlighted mantaining its own color. 
 
 
As a further assessment the multi probe information was compared with a 
previously reported pharmacophoric model,22, 43 showing a high degree of 
agreement 
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External Test Set Prediction Analysis. 
The external test set composed of 9 Hsp90 inhibitors (Appendix A Table A3) was 
applied to each of the eight 3-D QSAutogrid/R mono probe models to assess their 
predictive capability. In general, low errors of prediction were observed for all 
models (Table 5), and the correct activity trend was reproduced (Figure10).  
 
Table 5. Test Set predictions: SDEP values considering the optimal PCs; P: 
AutoGrid Probe; PC: optimal number of principal components/latent variables; 
SDEPEXT: standard deviation error of prediction (or root mean squared error of 
prediction, RMSEP) for the external test set. 
P PC SDEPEXT 
A 2 0.79 
C 2 0.79 
HD 2 0.78 
NA 2 0.80 
N 2 0.79 
OA 2 0.81 
e 2 0.79 
d 1 0.86 
 
 
As for the monoprobe models, the MP is endowed with good predictive 
capabilities (Table 6), reproducing with a good approximation the test set activity 
trend. 
 
 
Table 6. MPGRS. Multi Probe model Test Set predictions. 
P PCFL:SL SDEPEXT 
AutoGrid MP 1:2 0.81 
SDEP values considering the optimal first level and second level PCs. P: AutoGrid 
Multi-Probe; PCFL:SL: optimal first level and second level PC; SDEPEXT: standard 
deviation error of prediction (or root mean squared error of prediction, RMSEP) 
for the external test set. 
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A 
 
B 
 
C 
Figure 10. Experimental vs Predicted Test Set plots. A: from the A probe model at 
PC2; B: from the N probe model at PC2; C: from the OA probe model at PC2. 
 
 
 
 
  
99 
 
APPENDIX A 
Table A1. Hsp90 inhibitors data set: (15 compounds used as training set, see also 
Table A2; and 9 compounds as test set, see also Table A3) shown are the purine 
(A) and pyrazole (B) scaffold derivatives for which ATPase activity values are 
known. 
A) Purine
13
 scaffold derivatives 
 
entry 
PDB 
code 
R1 R2 R3 R4 R5 R6 
IC50 
ATPase(µM) 
1
a 1UY8 H n-butyl H OMe H H 75 
2
a 1UYC H n-butyl OMe H H OMe 41 
3
a 1UYD H n-butyl Cl OMe OMe OMe >200 
4
a 1UYE H 1-pentynyl Cl OMe OMe OMe >200 
5
a 1UYG F H OMe H H OMe 53.5 
6
a 1UYH F n-butyl OMe H H OMe 14.3 
7
a 1UYK F n-butyl H OCH2O bridge H 17.1 
8
b 1UY6 H n-butyl H OMe OMe OMe >200 
9
b 1UY7 H n-butyl H H OMe H >200 
10
b 1UY9 H n-butyl H OCH2O bridge H 15.3 
11
b 1UYF        
12
b 1UYI F 1-pentynyl OMe H H OMe 4.1 
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B) Pyrazole
14, 22
 scaffold derivatives  
 
entry 
PDB 
code 
R1 R2 R3 
IC50 
ATPase(µM) 
13
a 2BT0 Et 
 
Me 5.7 
14
a 2CCS Cl 1-piperazine H 8.2 
15
b 2CCT Cl 1-piperazine CONHEt 6.3 
16
a 2CCU Cl 
 
H 1.3 
 
C) 2-aminopyrimidine,
7
 triazine, pyrazole and N-aryl-benzimidazolone
20
 
entry 
PDB 
code 
 
IC50 
ATPase(µM) 
17
a 3B25 
 
9.6 
18
a 3B26 
 
6.9 
19
b 3B27 
 
0.75 
20
a 3B28 
 
3 
101 
 
21
a 3OWB 
 
0.88 
22
a 3OWD 
 
0.55 
23
b 3OW6 
 
85 
24
b
 4EGK 
 
0.2 
a
Compounds used as training set 
b
Compounds used as test set
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Table A2. Training Set.  
entry PDB 
Code 
IC50 
ATPase(μM) 
pIC50
a 
1 1UY8 75 4.12 
2 1UYC 41 4.39 
3 1UYD 200 3.70 
4 1UYE 200 3.70 
5 1UYG 53.5 4.27 
6 1UYH 14.3 4.84 
7 1UYK 17.1 4.77 
13 2BT0 5.7 5.24 
14 2CCS 8.2 5.09 
16 2CCU 1.3 5.89 
17 3B25 9.6 5.02 
18 3B26 6.9 5.16 
20 3B28 3 5.52 
21 3OWB 0.88 6.06 
22 3OWD 0.55 6.26 
a
pIC50 = -Log [IC50ATPase(µM) x 10
-6
] 
 
Table A3. Test Set  
entry 
PDB 
Code 
IC50 
ATPase(μM) 
pIC50
a 
8 1UY6 200 3.70 
9 1UY7 200 3.70 
10 1UY9 15.3 4.82 
11 1UYF 30 4.52 
12 1UYI 41 5.39 
15 2CCT 6.3 5.20 
19 3B27 0.75 6.12 
23 3OW6 85 4.07 
24 4EGK 0.2 6.28 
b
pIC50 = -Log [IC50ATPase(µM) x 10
-6
] 
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Chapter VIII 
Hsp90 Inhibitors (II). Combining ligand-based and structure-based 
approaches for Virtual Screening application 
Antonia Caroli, Flavio Ballante, Richard B. Wickersham III, Federico Corelli And 
Rino Ragno 
Journal of Chemical Information and Modeling, (2013, submitted) 
 
Preamble 
The present Chapter summarizes efforts for the discovery of hit compounds with 
molecular scaffolds previously untested as Hsp90 inhibitors. To select potential 
new Hsp90 inhibitors, three-dimensional quantitative structure-activity 
relationships (3-D QSAR), ligand-based (LB) and structure-based (SB) alignments 
methods, and a LB-SB virtual screening (LB-SB-VS) protocol were applied. Then, 
the NCI Diversity Set was virtually screened employing the LB-SB-VS strategy, 
and 80 molecules were selected for enzyme-based biological assays. Among the 
tested molecules, four derivatives showed IC50 values ranging between 18-63 µM. 
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Introduction 
Computer-aided Virtual (in silico) Screening (VS) represent a powerful technique 
in identifying new bioactive compounds from large chemical databases. Currently, 
different VS strategies can be employed on the basis of the source data: when 3-D 
structures are unavailable, ligand based (LB) methods, such as QSAR, 3-D QSAR 
and pharmacophore-based procedures are commonly used; otherwise when 3-D 
information is available, structure based (SB) protocols, like ligand-protein 
docking procedures, are mainly applied. Anyway, it should be considered that 
molecular docking has a significant limitation represented by the interdependence 
between sampling and scoring as generally implemented. Indeed, this 
interdependence limits the rate of success for the identification of near-native poses 
in virtual screening. To enhance the VS performance, another strategy is to use 
either SB and LB methods, as for the VS application characterizing the study 
herein presented, in which a combination of Autodock (SB) and Surflex-Sim (LB) 
scoring functions were used jointly with the predictive ability of previously built 3-
D QSAR models (Chapter VII). 
 
Methodology overview 
As reported in Chapter VII, several three-dimensional quantitative-structure 
activity relationship (3-D QSAR) models were built and externally validated using 
a data set composed of 24 Hsp90 inhibitors, 15 of which were used as training set 
and the other 9 as test set. These models were implemented, as a predictive tool, in 
a virtual screening procedure (Figure 1) used to predict the inhibitory ability of 
1785 compounds (NCI Diversity Set) suggesting which of these should be chosen 
to be biologically assayed. Considering the unavailability of 3-D informations, two 
different alignment procedures, a LB methodology using Surflex-sim
1
 and a SB 
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methodology using AutoDock4,
2
 previously validated, were adopted to predict 
their binding poses (see Alignment rules paragraph), in order to be subsequently 
tested by the 3-D QSAR models. Therefore two different sets of predicted binding 
conformations were used as external test sets for the 3-D QSAR models, yielding 
two sets of predicted pIC50 values. By means of a consensus scoring procedure in 
which either the predicted pIC50 values and the predicted free binding energy from 
the Autodock4 docking were used, 80 molecules were then selected for enzyme-
based biological assays. Among the tested molecules, four derivatives showed IC50 
values in the micromolar range. 
 
Alignment Rules: 
To obtain the pose of molecules with unknown binding modes (NCI Diversity Set), 
either ligand based (LB) and structure based (SB) alignment procedures were 
applied, using Surflex-sim and AutoDock4 respectively, applying a protocol 
completely described in a previous work.3 
 
Virtual Screening (VS). 
By the application of the alignment protocol on the NCI Diversity Set, two 
different binding poses, derived from Surflex-Sim and AutoDock4, were obtained 
for each compound, therefore two different sets were composed and predicted by 
the selected 3-D QSAR models: A, N, OA and MP (as specified in Chapter VII). A 
rank by rank strategy
4
 was then applied, considering the predicted pIC50 values 
together with the corresponding predicted free binding energy released by 
AutoDock4 to select the 80 top ranked compounds which were selected for 
biological investigations. From these, four molecules (NCI23128, NCI23128, 
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NCI117285 and NCI170578) showed IC50 values between 18 and 63 µM (Table 1), 
confirming the consistence of the applied strategy towards untested molecules. 
 
 
 
Figure 1. Computational procedure. 
 
 
110 
 
Table 1. Molecular structure and biological activity of the most active compounds 
selected by the VS protocol. 
 ID 
IC50 
[µM] 
 
NCI23128 18 
 
NCI610930 32 
 
NCI117285 49 
 
NCI170578 63 
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Binding mode analysis of new HSP90 inhibitors.  
Among the most active screened compounds, attention was focused on 
NCI610930, NCI170578 and NCI117285 endowed with interesting scaffolds for 
new Hsp90 inhibitors. Investigating the activity contribution plots obtained from 
the selected compounds, it was possible to highlight how the quantitative models 
(A, N, OA) predicted the interactions of these test set molecules helping to define 
the crucial interaction during the binding mode analysis. As shown in Figure 2, 
starting from the most active compound to the least active (NCI610930  
NCI117285  NCI170578), a positive predicted activity contribution area (green 
surface, Figure 2), in the proximity of LYS58, ILE96, and GLY97, decreases in 
magnitude jointly with the biological response; while considering NCI170578 and 
NCI117285 (the least active compounds) another positive predicted activity 
contribution area appeared near LEU48, VAL186, THR 184, ASP93, SER 52, and 
LEU48. These results were a further confirmation of the importance of these two 
residues’ series, as previously predicted by the 3-D QSAR models (Chapter VII). 
Moreover, NCI610930 and NCI170578 are respectively a dibenzofurandione and 
a dibenzothiophene derivatives, that could be ascribed to the tricyclic series of 
Hsp90 inhibitors, recently identified
5
 as a new interesting scaffold for Hsp90 
inhibitors, confirming the predictive capability of the applied VS protocol. 
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NCIn° Probe A Probe N Probe OA 
610930 
   
1UYC 
117285 
   
1UY8 
170578 
   
1UY8 
Figure 2. Predicted activity contribution plots (solid: 75%, positive: green, negative: 
yellow), overlapped with PLS coefficients plots (mesh: 65%, positive: red, negative: 
blue) obtained from the used 3-D QSAR models at the selected PC,
6
 for the most active 
screened compounds in their BC system (protein and pose): NCI610930 in 1UYC, 
NCI117285 and NCI170578 in 1UY8. 
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Introduction 
My first research abroad was conducted for six months (beginning: September 
2012, end: March 2013) at the Laboratoire d'Ingénierie et Moléculaire 
Pharmacologique Biochimie (LIMBP) of the Université de Lorraine Metz 
(France), directed by Prof. Gilbert Kirsch, and characterized by the application of 
organic synthesis to obtain new thienopyrimidinone derivatives as potential 
inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2). These new 
compounds were designed as a consequence of the informations obtained from the 
analyses characterizing the Chapter V. In particular, among the several applied 
synthesis, here will be reported those concerning the 3 compounds (7a, 7b, 7c) 
which were finally obtained and biologically tested for their inhibitory activity 
against EGFR and VEGFR-2. 
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Synthesis of compounds 7a, 7b, 7c as new potential VEGFR-2 inhibitors 
 
Ethyl(4-nitrophenoxy)acetate (1) 
 
 
A solution of 4-nitrophenol (150 mmol) in DMF (300 ml) was firstly obtained, 
then potassium carbonate (225 mmol) and etilbromoacetate (165 mmol) were 
added and the mixture was stirred at reflux (80°C) for 2h. Then, the reaction 
mixture was cooled, poured over ice-water, filtered at a reduced pressure using a 
Buchner flask and dried in vacuo. 
 
 
Ethyl(4-nitrophenoxy) 
Molecular Weight 225.198 
 
Aspect 
Pale yellow 
solid 
Yield 95% 
1
H NMR (250MHz, DMSO): δH 8.18 (d, 2H), 7.17 (d, 2H), 4.98 (s,2H, CH2), 4.17 
(q, 2H, CH2), 1.20 (t, 3H, CH3) 
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(4-Nitrophenoxy) acetic acid (2) 
 
 
A solution of Ethyl(4-nitrophenoxy)acetate (136 mmol) in absolute ethanol (255 
ml) was firstly composed, then sodium hydroxide 1M (255 mmol) was added and 
the mixture was stirred at reflux (85°C) for 2h. Subsequently, the reaction mixture 
was stirred at room temperature for 1h, poured over ice-water and acidificated with 
HCl 2N to adjust the pH value to 6. Finally the mixture was filtered at a reduced 
pressure using a Buchner flask and the solid phase was washed with water and 
dried on vacuum at 60°C. 
 
 
(4-Nitrophenoxy) acetic acid 
Molecular Weight 197 
 
Aspect Yellow solid 
Yield 93% 
1
H NMR (250MHz, DMSO): δH 13.23 (s, 1H), 8.20 (d, 2H), 7.13 (d, 2H), 4.87 (s, 
2H) 
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2-Aminothiophene-3-carboxamide (3) 
 
 
Two different procedures, characterized by different heating methods, were applied 
for the synthesis of 2-Aminothiophene-3-carboxamide. The first was conducted 
heating under reflux, the second was microwave assisted. 
 
Procedure 1): A stirred mixture of 2-cianoacetamide (200 mmol), 1,4-dithiane-
2,5-diol(100 mmol) in Methanol(80 ml) and Triethylamine (10 ml) 
was heated at reflux (65 °C) for 3h. After cooling to room 
temperature, the mixture was concentrated under reduced pressure, 
poured over ice-water, filtered and dried in vacuo. 
 
Procedure 2): A mixture of 2-cianoacetamide (200mmol), 1,4-dithiane-2,5-diol 
(100 mmol) in Methanol(80 ml) and Triethylamine (5 ml) was 
heated under microwave irradiation (50 °C, 100W x 10 min). After 
cooling to room temperature, the mixture was concentrated under 
reduced pressure, poured over ice-water, filtered and dried in vacuo. 
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2-Aminothiophene-3-carboxamide 
Molecular Weight 142 
 
Aspect Brown solid 
Yield 
Reflux: 74% 
Microwave:79% 
1
H NMR (250MHz, DMSO): δH 7.19 (s, 3H), 7.02 (d, 1H), 6.72 (bs, 1H), 6.2 (d, 
1H) 
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2-{[(4-Nitrophenoxy)acetyl]amino}-3-thiophenecarboxamide (4) 
 
 
 
Reaction mixture 1 : 
A solution of 2 (100 mmol) and amylene stabilized chloroform ( added until 
solubilization of the acid) was firstly obtained. Then thionyl chloride 99.5+% (73 
ml) was added and the mixture was stirred at reflux (60°C) for 2h. Subsequently, 
the reaction mixture was concentrated under reduced pressure, to obtain (4-
nitrophenoxy)acetyl chloride (97 mmol), a red colored solid. 
Reaction mixture 2: 
Another solution of 3 (90 mmol) and amylene stabilized chloroform (added until 
solubilization of the acid) was obtained. Then Triethylamine (31 ml) was added, 
then mixture was stirred and cooled to 10 °C. At this point (4-nitrophenoxy)acetyl 
chloride was resolubilized in amylene stabilized chloroform and slowly added to 
the reaction mixture 2 at 10 °C. Following the addition, the mixture was stirred at 
room temperature for 1h, then poured in ice/water and filtered to obtain the final 
compound 4. 
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(4-nitrophenoxy)acetyl chloride 
Molecular Weight 215.591 
 
Aspect Red solid 
Yield 97% 
 
 
 
2-{[(4-Nitrophenoxy)acetyl]amino}-3-thiophenecarboxamide 
Molecular Weight 321.309 
 
Aspect Goldenrod solid 
Yield 76% 
1
H NMR (250MHz, DMSO): δH 13.00(s, 1H), 8.28(d, 2H), 7.96(s, 1H), 7.61(s,1H) 
7.45(d, 1H), 7.27(d, 2H), 7.04(d, 1H), 5.06(s, 2H) 
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2-{[(4-aminophenyl)acetyl]amino}-3-thiophenecarboxamide (5) 
 
 
A 500 ml, three-necked flask, equipped with a mechanical stirrer, thermometer, 
and a reflux condenser, connected to an argon line was charged with 4 (67 mmol), 
ammonium chloride (1.79 g), isopropanol (134 ml), water (27 ml), and acetic acid 
(2.2 ml). The mixture was stirred and warmed to 60°C. At this point the heat was 
turned off and iron powder (22.44 g) was added in small portions (temperature 
held steady at 60-65°C during the addition). Following the addition the mixture 
was refluxed for 30 min and stirred at room temperature overnight. The hot 
reaction mixture was diluted with 223 ml of warm ethyl acetate and filtered 
through a pad of Super Cel. The solids were washed with 2 x 110 ml of warm ethyl 
acetate. The filtrate and the washes were then extracted with 2 x 110 ml of water, 
dried over magnesium sulfate and concentrated. 
2-{[(4-aminophenyl)acetyl]amino}-3-thiophenecarboxamide  
Molecular Weight 291.326 
 
Aspect dark grey solid 
Yield 51% 
1
H NMR (250MHz, DMSO): δH 12.88(s, 1H), 7.91(s, 1H), 7.53(s, 1H), 7.43(d, 
2H), 7.01(d, 1H), 6.83-6.79(m, 2H), 6.55-6.51(m, 2H), 4.71(bs, 2H), 4.66(s, 2H),  
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2-(4-aminophenoxymethyl)-3H-thieno[2,3-d]pyrimidin-4-one (6) 
 
 
A stirred mixture of 5 (34 mmol), sodium hydroxide 4N (113.5 ml), 
Dimethylformamide (113.5 ml) was heated at reflux (100 °C) for 3h, then cooled at 
room temperature and diluited with water (680 ml). At this point the reaction 
mixture was acidificated with HCl 2N to adjust the pH value to 6 and then filtered 
to obtain 4.86 g (17 mmol) of filtrate. The filtrate was then extracted with ethyl 
acetate and the organic phase was washed with a saturated sodium chloride 
solution, dried with magnesium sulfate and finally filtered to obtain 0.3g (1 mmol) 
of 6. 
 
 
2-(4-aminophenoxymethyl)-3H-thieno[2,3-d]pyrimidin-4-one  
Molecular Weight 273.310 
 
Aspect olive drab solid 
Yield 53% 
1
H NMR (400MHz, DMSO): δH 12.65(bs, 1H), 7.61-7.58(m, 1H), 7.40-7.39(m, 
1H), 6.78-6.74(m, 2H), 6.53-6.49(m, 2H), 4.87(s,2H), 4.71(bs, 2H) 
  
124 
 
3-[4-({4-oxo-3H-thieno[2,3-d]pyrimidin-2-yl}methoxy)phenyl]-1-phenylurea (7a) 
 
 
 
Reaction mixture 1: 
2 mmol of 6 were dissolved in amylene stabilized chloroform (8 ml) to compose 
the first reaction mixture. 
Reaction mixture 2: 
2.4 mmol of phenylisocyanate were dissolved in amylene stabilized chloroform 
(4ml) to form the second reaction mixture 
Reaction mixture 2 was added drop-wise to reaction mixture 1, the resulting 
mixture was stirred at room temperature overnight. Since the TLC showed an 
uncompleted reaction, more phenylisocianate (1.2 mmol) was added and the 
mixture was stirred for 12 h, filtered and then purified by crystallization with 
dioxanne obtaining 0.40 g of 7a. 
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3-[4-({4-oxo-3H-thieno[2,3-d]pyrimidin-2-yl}methoxy)phenyl]-1-
phenylurea 
Molecular Weight 392.431 
 
Aspect Light grey solid 
Yield 50% 
1
H NMR (400MHz, DMSO): δH 12.71(s, 1H), 8.61(s, 1H), 8.52(s, 1H), 7.6(d, 1H), 
7.45-7.36(m, 5H), 7.27(t,2H), 6.99-6.95(m, 3H), 4.99(s, 2H) 
 
MS (ESI, [M+Na]
+
) 
m/z for C20H16N4NaO3S 
theoretic: 415.0840 
obtained: 415.0834 
Microanalysis:  
 
3% of H2O C H N S 
theoretic: 58,76 4,39 13,70 7,84 
obtained: 58,94 3,54 13,29 7,01 
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1-(4-fluorophenyl)-3-[4-({4-oxo-3H-thieno[2,3-d]pyrimidin-2-yl}methoxy)phenyl] 
urea (7b) 
 
 
The same procedure as 7a was applied, but in this case was not necessary to add 
more 4-fluoro-phenylisocyanate. After filtration, the solid was purified by 
crystallization in MeoH obtaining 0.33g of 7b. 
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1-(4-fluorophenyl)-3-[4-({4-oxo-3H-thieno[2,3-d]pyrimidin-2-yl} 
methoxy)phenyl]urea 
Molecular Weight 410.422 
 
Aspect Light grey solid 
Yield 40% 
1
H NMR (400MHz, DMSO): δH 12.66(s, 1H), 8.64(s, 1H), 8.51(s, 1H), 7.6(d, 2H), 
7.46-7.36(m, 4H), 7.1-6.97(m, 4H), 4.99(s, 2H) 
MS (ESI, [M+Na]
+
) 
m/z for 
C20H15FN4NaO3S 
theoretic: 433.0746 
obtained: 433.0737 
Microanalysis:  
 
3% of H2O C H N S 
theoretic: 56,77 3,90 13,23 8,00 
obtained: 56,97 3,59 13,39 7,62 
 
  
128 
 
1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[4-({4-oxo-3H-thieno[2,3-d]pyrimidin-2-
yl}methoxy)phenyl]urea (7c) 
 
The same procedure as 7a was applied, but quantities were different: 
Reaction mixture 1: 
0.5 mmol of 6 were dissolved in amylene stabilized chloroform (2 ml) to compose 
the first reaction mixture 
 
Reaction mixture 2: 
0.6 mmol of 4-Chloro-3-tryfluoromethyl-phenylisocyanate were dissolved in 
amylene stabilized chloroform (1ml) to form the second reaction mixture 
Reaction mixture 2 was added drop-wise to reaction mixture 1, the resulting 
mixture was stirred at room temperature overnight. Since the TLC showed an 
uncompleted reaction, was added trietylamine (0.245ml), but there wasn’t any 
improvement. The mixture was then concentrated under reduced pressure, 
dissolved with diethylether, filtrate and the obtain solid was washed with methanol 
to obtain 0.13g of 7c. 
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1-[4-chloro-3-(trifluoromethyl)phenyl]-3-[4-({4-oxo-3H-thieno[2,3-
d]pyrimidin-2-yl}methoxy)phenyl]urea 
Molecular Weight 494.874 
 
Aspect Light grey solid 
Yield 52% 
1
H NMR (400MHz, DMSO): δH 12.57(bs, 1H), 9.07(s, 1H), 8.65(s, 1H), 8.09(s, 
1H), 7.64-7.58(m, 3H), 7.41-7.38(m, 3H), 7.01-6.99(m, 2H), 5.00(s, 2H) 
19F NMR (376 MHz, DMSO): δF -61.44(s, 3F) 
MS (ESI, [M+Na]
+
) 
m/z for 
C21H14ClF3N4NaO3S 
theoretic: 517.0325 
obtained: 517.0323 
Microanalysis:  
 
 C H N S 
theoretic: 50.97 2.85 11.32 6.48 
obtained: 51.08 2.77 11.56 6.41 
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Biological evaluation for compounds 7a, 7b, 7c 
 
Compounds 7a, 7b and 7c were investigated for their inhibitor activity against 
either EGFR and VEGFR-2, at the Institut de Chimie Pharmaceutique Albert 
Lespagnol, Université Lille 2, by the “Groupe de Recherche Interdisciplinaire 
Innovation et Optimisation Thérapeutique EA4481” under the supervision of Pr. 
Patrick Depreux. 
Inhibition activities were derived against EGFR (purified from A431 cell 
membranes) and VEGFR-2 (recombinant human protein) by quantifying the 
enzymatic tyrosine kinase activity, from the incorporation of radiolabeled ATP 
([γ32P]ATP] on a peptide substrate containing tyrosine residues [Poly(Glu, Tyr) 
4:1] (Figure 1). Due to the possibility that other endogenous proteins may be 
phosphorylated, a further test was performed without PolyGluTyr and the result 
was subtracted from the value obtained in the presence of the screened compound. 
The reactions took place in a “Multiscreen® Durapore®” (MilliporeTM) 96-well 
plate. The wells were pre-wetted with 100µL of water, and the receptors (20 ng of 
EGFR and 10ng of VEGFR-2) were pre-incubated in the presence or absence of 
the test compound (1-dose mode: 10 µM), previously dissolved in DMSO, for 5 
minutes at 37 °C. The final DMSO concentration was 0.1%. Two different 
solutions (Table 1) were prepared for each enzyme and added (50 µL) to start the 
reactions. After 1 hour (at 28 °C) the reactions were stopped by adding 20 µL of 
trichloroacetic acid (TCA) 100% which caused precipitation lasting 30 minutes 
followed by the radioactivity count procedure. As mentioned above tests were 
accomplished with and without the substrate, in order to eliminate the contribution 
of endogenous proteins to the radioactivity. For each compound, inhibitory activity 
(%) against EGFR and VEGFR were determined (Table 2). 
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Table 1. Used reagents 
EGFR 
HEPES 50 mM pH 7,5, BSA 0,1 mg.mL-1, MnCl2 5 mM, 
Na3VO4 100 μM, DTT 0,5 mM, poly(Glu4/Tyr) 250 μg.mL-1, 
ATP 5 μM, [γ32P] ATP 0,5 μCi 
VEGFR-2 
Tris 50 mM pH 7,5, BSA 25 μg.mL-1, MnCl2 1,5 mM, MgCl2 10 
mM, Na3VO4 100 μM, DTT 2,5 mM, poly(Glu4/Tyr) 250 μg.mL-
1, ATP 5 μM, [γ32P] ATP 0,5 μCi, β-glycérophosphate 5 mM. 
 
 
 
Figure 1. Assay of protein kinases using radiolabeled ATP. 
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Table 2. Structures and either EGFR, VEGFR-2 inhibitory activity of thieno[2,3-
d]pyrimidinones 7a-7c. 
 
# R R1 
% Inhibition @ 10 µM 
EGFR VEGFR-2 
7a H H n.a.
a 
9% 
7b F H n.a.
a
 5% 
7c Cl CF3 n.a.
a
 13% 
a
 Not active. No inhibition was observed up to 10 µM of the tested compound. 
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Introduction 
My second research activity abroad, was conducted for three months (beginning: 
August 2013, end: October 2013) at the Marshall Lab., directed by Prof. Garland 
R. Marshall, in the Department of Biochemistry and Molecular Biophysics of 
Washington University School of Medicine in St. Louis (MO, USA) to investigate 
the activity profile of new Histone Deacetylases (HDACs) inhibitors. 
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HDACIs activity investigation 
 
In vitro determinations were conducted applying the Electrophoretic mobility shift 
assay (EMSA)
1
 by using the LabChip
®
 EZReaderII
2
 instrument (Figure 1, Caliper-
Perkin Elmer
®
). 
  
  
Figure 1. The LabChip
®
 EZReaderII. 
 
Fundamentally, three main objectives were accomplished: 
a) Training on the EZReaderII instrument 
b) Define the Enzymatic assays protocol for HDACs 
c) Start the inhibitor titrations HDAC3 and HDAC6 isoforms  
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LabChip
®
 EZReaderII: 
The LabChip
®
 EZReaderII combines the basic principles of capillary 
electrophoresis in a microfluidic environment to analyze enzymatic assays with or 
without the addition of a termination or quenching reagent. The core of the 
instrument is the so-called “Chip” (Figure 2), which is characterized by: 
 6 Upstream and 2 Downstream Electrode Wells (Figure 2A); 
 12 Sippers (Figure 2B); 
 a detection window (Figure 2C) 
 a network of miniaturized channels (like those characterizing the detection 
window, Figure 2C) through which fluids and chemicals are moved to 
perform experiments; 
 
A 
 
B 
 
C 
Figure 2. The LabChip
®
 EZReaderII Chip. 
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As shown in Figure 3, the whole analysis process can be summarized in the 
following steps: 
1) using vacuum pressure, reactions are sipped, from the sample wells through 
fused silica sippers located in the bottom of the chip;  
2) both electrokinetics and pressure, are exerted on the chip to generate fluid 
motion through the microchannels. By applying an electric-potential difference 
across the separation channel, fluorescently labeled substrates and products are 
separated by electrophoresis and detected by LED-induced fluorescence; 
3) both the substrate and the formed product are detected and measured for each 
sample. The amount of product is determined as 
                    
                                
. 
 
Figure 3. Overview of the Mobility Shift Assay performed by the LabChip
®
 
EZReaderII. 
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Materials and Methods 
Screened Compounds: 
Several enzymatic assays were performed to investigate the HDAC 3 and 6 
inhibitor activities (IC50 values), of a new molecular set (Table 1) characterized by 
chemo-physical properties ascribable to anti-HDAC activity, as follows : 
 new largazole derivatives, synthetized in the Marshall lab.,  
 new compounds synthetized in the laboratory supervised by Prof. Antonello 
Mai, (Department Of Chemistry and Drug Technologies, Faculty of 
Pharmacy and Medicine – Sapienza Università di Roma). 
Moreover, three stock compounds: SAHA, Tubastatin A and Entinostat, from 
Sellekchem
®
 tubes, were used as standard compounds. 
 
Table 1. List of screened compounds. 
# Cpd 
Stock 
Solution mM  
in 100% 
DMSO 
 
# Cpd 
Stock 
Solution mM  
in 100% 
DMSO 
1 MC1716 10 
 
16 MC2776 10 
2 MC1723 10 
 
17 MC2780 10 
3 MC1739 10 
 
18 MC2984 10 
4 MC1742 10 
 
19 MC3004 20 
5 MC1746 10 
 
20 MC3031 10 
6 MC1862 10 
 
21 MC3050 10 
7 MC2122 20 
 
22 MC3079 10 
8 MC2126 10 
 
23 SD-L-148 20 
9 MC2129 10 
 
24 SD-L-256 10 
10 MC2195 20 
 
25 SDM141 20 
11 MC2427 10 
 
26 SDM146 20 
12 MC2625 10 
 
27 ENTINOSTAT
a 
50 
13 MC2664 10 
 
28 SAHA
a 
100 
14 MC2726 10 
 
29 TUBASTATIN A
a 
100 
15 MC2727 10 
 
   
a
Stock compounds: from Selleckchem
®
 Tubes 
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The synthetized compounds (originally as powder) were solubilized in 100% 
DMSO to get the final micromolar concentrations (mM, Table 1), moreover 
different solutions, required for the enzymatic assays, were prepared: 
1. Separation Buffer 
2. Reaction Buffer 
3. Dye Marker 
4. Substrate Mix 
5. Enzyme Mix 
Overall, the “relationship” between the instrument and the necessary components 
can be represented like the chart in Figure 4: 
 
 
Figure 4. The hardware and chemical protagonists characterizing the assays. 
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Separation Buffer: 
The separation buffer is the solution that runs through the machine and the chip. It 
is used mainly to preserve the separation conditions and prevent peptide sticking in 
the microfluidic chip; since it is stable at room temperature for seven days, a fresh 
sterilized solution (at least 200 mL, Figure 5) was primed into the EZReaderII 
every week.  
 
Figure 5. Recirculation system for the separation buffer. 
 
Differently, the chip required much more attention, needing to be “prepared” 
(firstly washed with milliQ water and separation buffer, then re-charged with the 
latter) every week or after 40 hours of run time.  
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A 
 
B 
 
C 
Figure 6. Chip preparation: every week or after 40 hours of run time it needs to be 
completely washed with milliQ water (A) and separation buffer (B), then dried, 
charged with new separation buffer and finally installed in the EZReaderII 
instrument (C). 
 
The separation buffer (10mM EDTA) was obtained following the company 
guidelines, by merging a pre-separation buffer (1mM EDTA) with a solution of 
EDTA 0.5M (pH 8), whose compositions are described in Table 2: 
 
Table 2. Separation Buffer. The solution was finally sterilized using a 0.2 µm pore 
filter membrane. 
Final solution 
Intermediate 
solution 
Composition 
Separation 
Buffer (10mM 
EDTA) 
 
Pre-separation 
buffer 
 100mM HEPES, pH 7.3 
 0.015% Brij-35 
 1mM EDTA 
 0.1%CR-3 
 5% DMSO 
 
EDTA 0.5M 
 milliQ water 
 EDTA (powder) 
 pH adjusted to 8.0 using NaOH 
(pellets) 
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Reaction Buffer (RxnB): 
The reaction buffer (RxnB) represents the solution to be added into the plate wells 
together with the reagents. It was prepared following the company guidelines 
(Table 3).  
Table 3. Reaction buffer. The solution was finally sterilized using a 0.2 µm pore 
filter membrane. 
Final solution 
Intermediate 
solution 
Composition 
Reaction Buffer 
0.01 % w/v 
BSA
a
 
Base buffer 
 25mM Tris-HCl pH 8.0 
 137mM NaCl 
 2.7 mM KCl 
 1 mM MgCl2 
 
BSA
a
 1% w/v 
 milliQ water 
 BSAa powder 
 
a
BSA: Bovine Serum Albumine 
 
Dye Marker: 
The Dye marker is the 1X peptide solution used to create the plate row markers 
during the assay: specifically the H219 peptide (Table 4) was used to accomplish 
this role. 
 
Substrate Mix: 
The substrate mix is the solution containing the peptide to be deacetilated. For the 
assays, H218 and H219 peptides (Table 4) were used in the case of HDAC3 and 
HDAC6 respectively. As reported above, H219 was utilized also as the dye 
marker.  
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Table 4. The used substrates: H218 and H219 peptides. 
H218 H219 
5-FITC-AHA-TSPQPKK(Ac)-CONH2 
 Derived from p53 
 1.5 mM in 100% DMSO 
5-FITC-AHA-LGKGGAK(Ac) -CONH2 
 Derived FROM Histone 4 
 1.5 mM 100% DMSO 
 
Enzyme Mix: 
This is the solution containing the enzyme (HDAC) and the RxnB. 
 
Assay plate: 
For all the assays, Corning
®
 384 assay plates (Figure 7) were utilized. 
 
Figure 7. Used assay plates. 
Corning
®
 (#3673) Specifics 
 
 384 assay plate 
 Non-binding surface 
 Round bottom 
 White polystirene 
 Working volume: 
5-40 µL 
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Enzyme assays workflow: 
The applied workflow involved, firstly, the enzyme titration step, followed by the 
enzyme inhibitor titration. 
 
Enzyme titration: 
Enzyme titration (Figure 8) is necessary to: 
 determine the enzyme concentration, for a 30% substrate conversion, to be 
used during the inhibitory titration; 
 establish the assay parameters as: Pressure, Downstream Voltage, Upstream 
Voltage, Buffer Sip, Sample/Marker Sip Time, Final Delay, Peak Order, 
Cycles 
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Figure 8. Enzyme titration workflow. 
 
Enzyme titration was performed in 6-dose mode with 3-fold serial dilution, using 
2-replicates; since HDAC 3 and HDAC 6 are characterized by different activities, 
different ranges were used (Figure 9). Initially, different 2X enzyme mix solutions 
were obtained by diluting the stock enzyme solution with RxnB and placed in plate 
wells, then an equal volume of 2X peptide mix was added to each well to reach the 
final (1X) desired concentration and start the reaction (deacetylation). 
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Figure 9. Enzyme titration was conducted in 6-dose mode with 3-fold serial 
dilution, starting from 20 ng/µL and 30 ng/µL for HDAC 3 and HDAC 6 
respectively. 
 
Then, the plate was placed in the LabChip
® 
EZReaderII instrument, previously 
“charged” with the dye marker, to start a 45 cycles detection (≈ 1 hour), following 
the reaction in a real-time mode (example in Figure 10) and finally obtain 
conversion rates (example in Figure 11). The whole procedure was optimized in 
order to use for each well a total volume equal to 20 µL (10 µL of 2X enzyme mix 
+ 10 µL of 2X peptide mix).  
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Figure 10. Enzyme titration outputs. The reaction is monitored, as it progresses, by 
sequentially “sipping” samples onto the chip at various time intervals (cycles): 
removal of acetyl groups from peptide substrates produces distinct mobility-shifts. 
Three different peak types are detectable for each cycle: the marker peaks (red 
contoured), the product peaks (green contoured) and the substrate peaks (yellow 
contoured). Since the chip is characterized by 12 sippers, 12 different wells (6 for 
each row) were monitored at the same time: each color represents data from a 
different reaction well.  
 
  
Cycle 
45
th
 Cycle 
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Figure 11. Enzyme titration results expressed as substrate conversion rates. As for 
example are shown the results obtained from one HDAC3 titration (Enzyme from 
Sigma-Aldrich™, Product N.SRP0104, Lot N.5000320524, specific activity ≥3000 
pmol/min/µg). In this specific case the characterizing enzyme concentration of well 
n. 3 (2.2 ng/µL, compare with Figure 9) was used for the inhibitor titration, since it 
was the closest to determine a conversion rate equal to 30%. 
 
Once determined the enzymatic concentration capable to convert (deacetylate) a 
substrate quantity close to 30%, it was possible to proceed for the inhibitor 
titration. 
Inhibitor titration: 
A total of 32 titrations for HDAC 3 and 24 titrations for HDAC 6 were performed, 
following the screening scheme specified in Table 5. Compounds were tested in 
10-dose IC50 mode with 3-fold serial dilution starting from 30 µM. For each 
replicate, well plates n. 11 (23) and 12 (24) were used as 0% inhibition and 100% 
inhibition controls, respectively (Figure 12). Each well was charged with a total of 
15µL of reactions following the sequence shown in Figure 13. After 1 hour of 
incubation reactions were stopped by adding, to each well, 15 µL of termination 
buffer (reaction buffer + EDTA 10 mM), then the plate was introduced in the 
instrument to start the titration and derive conversion and inhibition rates (as for 
example Figures 14 and 15 show both the outputs for the 3
rd
 HDAC 3 screening). 
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Conversion rates were calculated considering the 
                    
                                
 
ratio, whereas inhibition rates were obtained considering the % of controls 
(averaging the results across sippers).  
 
Table 5. Screening scheme.
 
 
CPD ID Plate Row 
Screening 
N. 
Used Enzyme 
MC2984 A A, E 
1 
HDAC3 
HDAC6 
SDM 141 B B, F 
SDM 146 C C, G 
SD-L-256 D D, H 
SD-L-148 (Largazole) E I, M 
SAHA
a
 (Vorinostat) F J, N 
TUBASTATIN A
a
 G K, O 
ENTINOSTAT
a
 H L, P 
MC2727 A A, E 
2 
HDAC3 
HDAC6 
MC2726 B B, F 
MC2625 C C, G 
MC2664 D D, H 
MC2780 E I, M 
MC2776 F J, N 
MC3079 G K, O 
SAHA (Vorinostat)
a 
H L, P 
MC3031 A A, E 
3 
HDAC3 
HDAC6 
MC3004 B B, F 
MC3050 C C, G 
MC1742 D D, H 
MC1862 E I, M 
MC2126 F J, N 
MC2129 G K, O 
SAHA (Vorinostat)
a 
H L, P 
MC1716 A A, E 
4 HDAC3 
MC1723 B B, F 
MC1746 C C, G 
MC1739 D D, H 
MC2122 E I, M 
MC2427 F J, N 
MC2195 G K, O 
SAHA (Vorinostat)
a 
H L, P 
a
Selleckchem Tubes 
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Figure 12. Plate scheme applied during the inhibitor titration.  
 
Inhibition rates allowed to derive, for each screened compound, the characteristic 
inhibitory dose-response curve (Figure 16 and 19), the characteristic IC50 value 
(Table 6 and 7) and the relative inhibitory potency (Figures 17,18,20,21). 
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Figure 13. Protocol adopted to fill the wells. 
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Figure 14. HDAC 3
rd
 screening. Data Tracings (CCD2 signals). 
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A 
 
B 
Figure 15. HDAC 3
rd
 screening: Conversion rates (A) and inhibition rates (B) 
outputs. Rows and columns refers to those of the plate (compare with Figure 12 
and Table 5). 
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Figure 16. HDAC 3 inhibitory dose-response curves.  
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Table 6. HDAC 3: assays: inhibitory activities expressed as IC50 
and pIC50. 
HDAC 3 
 
IC50 pIC50 
Cpd COMPANY GRM COMPANY GRM 
SAHA 1st SCREEN 2.00E-08 2.18E-09 7.70 8.66 
SAHA 2nd SCREEN 2.00E-08 6.24E-10 7.70 9.20 
SAHA 3rd SCREEN 2.00E-08 2.92E-09 7.70 8.54 
SAHA 4th SCREEN 2.00E-08 6.17E-10 7.70 9.21 
TUBASTATIN A 3.00E-05 8.20E-07 4.52 6.09 
ENTINOSTAT 1.70E-06 7.73E-07 5.77 6.11 
MC1716 
 
2.34E-08 
 
7.63 
MC1723 
 
7.29E-08 
 
7.14 
MC1739 
 
3.72E-08 
 
7.43 
MC1742 
 
2.36E-08 
 
7.63 
MC1746 
 
3.81E-08 
 
7.42 
MC1862 
 
4.58E-08 
 
7.34 
MC2122 
 
6.81E-08 
 
7.17 
MC2126 
 
1.52E-07 
 
6.82 
MC2129 
 
1.15E-07 
 
6.94 
MC2195 
 
1.20E-07 
 
6.92 
MC2427 
 
1.57E-06 
 
5.80 
MC2625 
 
1.94E-07 
 
6.71 
MC2664 
 
7.25E-07 
 
6.14 
MC2726 
 
2.75E-07 
 
6.56 
MC2727 
 
2.73E-07 
 
6.56 
MC2776 
 
1.32E-05 
 
4.88 
MC2780 
 
1.01E-06 
 
5.99 
MC2984 
 
4.32E-07 
 
6.36 
MC3004 
 
1.63E-06 
 
5.79 
MC3031 
 
6.31E-08 
 
7.20 
MC3050 
 
7.25E-06 
 
5.14 
MC3079 
 
1.14E-05 
 
4.94 
SD-L-148 
 
1.44E-06 
 
5.84 
SD-L-256 
 
4.23E-07 
 
6.37 
SDM 141 
 
NAc 
 
NAc 
SDM 146 
 
NAc 
 
NAc 
NAc: No inhibition/activity not converged in a IC50 curve;  
NAv: Not Available 
157 
 
 
Figure 17. HDAC 3: standard compounds’ inhibitory profile, pIC50 values are 
reported on molar base. 
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Figure 18. HDAC 3: compounds Inhibitory Profile, pIC50 values are reported on 
molar base. 
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Figure 19. HDAC 6 inhibitory dose-response curves. 
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Table 7. HDAC 6 assays: inhibitory activities expressed as IC50 and 
pIC50. 
HDAC 6 
 
IC50 pIC50  
Cpd COMPANY GRM  COMPANY GRM   
     
     
SAHA 1st SCREEN NAv 1.02E-09 NAv 8.99 
SAHA 2nd SCREEN NAv 1.92E-09 NAv 8.72 
SAHA 3rd SCREEN NAv 1.31E-09 NAv 8.88 
TUBASTATIN A NAv 1.43E-08 NAv 7.85 
ENTINOSTAT NAv NAc NAv NAc 
MC1742 
 
4.30E-08 
 
7.37 
MC1862 
 
2.21E-08 
 
7.66 
MC2126 
 
5.38E-07 
 
6.27 
MC2129 
 
2.73E-07 
 
6.56 
MC2625 
 
1.70E-07 
 
6.77 
MC2664 
 
NAc 
 
NAc 
MC2726 
 
1.24E-07 
 
6.91 
MC2727 
 
1.32E-07 
 
6.88 
MC2776 
 
1.11E-05 
 
4.96 
MC2780 
 
3.03E-07 
 
6.52 
MC2984 
 
NAc 
 
NAc 
MC3004 
 
2.20E-07 
 
6.66 
MC3031 
 
4.68E-07 
 
6.33 
MC3050 
 
NAc 
 
NAc 
MC3079 
 
NAc 
 
NAc 
SD-L-148 
 
6.68E-06 
 
5.18 
SD-L-256 
 
8.01E-07 
 
6.10 
SDM 141
a
 
 
NAc 
 
NAc 
SDM 146
a
 
 
NAc 
 
NAc 
NAc: No inhibition/activity not converged in a IC50 curve; 
NAv: Not Available 
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Figure 20. HDAC 6 Standard compounds’ inhibitory profile, pIC50 values are 
reported on molar base. 
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Figure 21. HDAC 6: Compounds Inhibitory Profile, pIC50 values are reported on 
molar base. 
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